Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
Patent Information
- Application Number
- JP2024116639
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-30
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2039-12-02
AI Technical Summary
Current treatments for chronic lung diseases such as COPD and NCFB, particularly acute exacerbations, are inadequate, with existing therapies like antibiotics and corticosteroids leading to side effects and limited efficacy, and there is a lack of effective treatments for viral infections.
Administering polyclonal immunoglobulin directly to the respiratory tract via aerosolization to prevent or treat acute exacerbations by reducing inflammation and clearing potentially pathogenic microorganisms, avoiding systemic side effects and costs associated with intravenous administration.
Polyclonal immunoglobulin effectively reduces inflammation and clears pathogens in the respiratory tract, preventing acute exacerbations and reducing the risk of severe events, with localized administration offering higher concentrations and cost-effectiveness compared to systemic routes.
Smart Images

Figure 00000037_0000 
Figure 00000037_0001 
Figure 00000038_0000
Abstract
Description
[Technical field]
[0001] The present invention is in the field of preventing or treating acute exacerbations in chronic pulmonary diseases such as chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis by administration of polyclonal immune globulin to the airways, particularly by direct application of an aerosolized composition comprising polyclonal immune globulin. [Background technology]
[0002] Chronic lung diseases, especially those with exacerbations where infection is the main driver, are characterized by the difficulty of the subject to fully exhale air from the lungs. Patients with such chronic lung diseases experience shortness of breath due to difficulty in exhaling all the air from the lungs. Exhalation is exhaled slower than normal due to lung damage or narrowing of airways within the lungs. At the end of complete expiration, an abnormally high volume of air may still remain in the lungs. Chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis (NCFB) are examples of such chronic lung diseases. COPD is characterized by persistent airflow limitation, which is usually progressive and is associated with an increased chronic inflammatory response in the airways and lungs to harmful particles or gases. Exacerbations and comorbidities contribute to the overall severity of the disease in an individual patient [1]. NCFB is characterized by pathological dilation of the airways, identified clinically by x-ray manifestations of airway enlargement (i.e., by CT scan) [2]. Exacerbation is considered a key event in the progression of NCFB [3].
[0003] Acute exacerbations of respiratory symptoms frequently occur in patients with chronic lung diseases such as COPD and NCFB. These exacerbations are caused by bacterial or viral infections, which may coexist. During an exacerbation, there is a flare-up of inflammation, increased hyperinflation and gas trapping, reduced expiratory flow, and increased dyspnea. Other medical conditions, such as pneumonia, can exacerbate COPD exacerbations, for example.
[0004] Acute exacerbations of COPD are defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as an acute worsening of a patient's respiratory symptoms that exceeds the normal daily variation and results in further drug therapy [4]. The rate at which exacerbations occur varies greatly between patients. Chronicity of exacerbations in COPD patients favors tissue remodeling of the airways and contributes to disease exacerbation. These acute exacerbations correlate with high systemic inflammation and immune activation. The frequency of exacerbations increases as COPD severity worsens. Similarly, acute exacerbations may increase COPD progression, and furthermore, the inflammatory state created by acute exacerbations may increase susceptibility to further recurrent acute exacerbations. This results in a vicious cycle that drives COPD progression.
[0005] An NCFB exacerbation is defined as an acute worsening of one or more symptoms of NCFB beyond the normal day-to-day variation, e.g., the need for antibiotics in the presence of one or more symptoms such as increased cough, increased sputum volume, or worsening sputum purulence. A severe exacerbation is defined as the need for unplanned hospitalization or emergency department visit [3].
[0006] Patients with chronic lung diseases such as COPD or NCFB may present with recurrent airway infections that may lead to acute exacerbations. The most common cause of acute exacerbations of COPD is viral infection of the upper respiratory tract and tracheobronchial tree. The most common virus detected during COPD exacerbations is human rhinovirus (HRV) [5], which has been associated with the proliferation of bacterial airway microbiome [6]. The microbiota in COPD is generally highly diverse. Many different bacteria have been associated with COPD. However, the most pathogenic bacteria include influenza. These include Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus catarrhalis, Haemophilus parainfluenzae and Staphylococcus aureus. Furthermore, Pseudomonas aeruginosa (PA) has been described as one of the most harmful bacteria found in stable COPD and in patients with extremely severe airflow obstruction during exacerbations [7].
[0007] Treatment of COPD is based on inhaled corticosteroids (ICS), inhaled bronchodilators, including long-acting β2 agonists, and anticholinergics, including long-acting muscarinic receptor antagonists, as well as combinations of these. For example, severe COPD with a high risk of exacerbations is generally treated with a combination of all three classes of drugs. Although these therapies reduce exacerbations, patients receiving maximal inhalation therapy continue to experience exacerbations, and therefore new therapeutic approaches are needed. Indeed, ICS therapy is associated with side effects, including a high risk of pneumonia, oral candidiasis, hoarseness, and skin bruising. Other side effects include new-onset diabetes, progression of diabetes, and an increased risk of cataracts and tuberculosis. Long-term use is also associated with an increased risk of fractures in COPD patients [8]. Notably, ICS therapy only slightly reduces the frequency of exacerbations, and clinical trials have reported an increased risk of pneumonia with ICS use in COPD. This may be because ICS appears to reduce antiviral immunity, leading to mucus hypersecretion and increased bacterial load in the lungs [9].
[0008] In COPD patients with chronic bronchitis, phosphodiesterase 4 enzyme inhibitors (e.g., roflumilast) are added to the treatment of choice. Roflumilast is a nonsteroidal anti-inflammatory active substance designed to target both systemic and pulmonary inflammation associated with COPD. Roflumilast is indicated as an adjunct to bronchodilator therapy for the maintenance treatment of severe COPD associated with chronic bronchitis in adult patients with a history of frequent exacerbations.
[0009] Acute exacerbations of COPD are currently managed with pharmacotherapy including bronchodilators, ICS and antibiotics. ICS therapy is associated with side effects as discussed above. Antibiotics are used to treat bacterial airway infections to reduce the occurrence and severity of exacerbations. Macrolides also have anti-inflammatory effects and are used in patients with severe COPD and a history of frequent exacerbations. However, long-term macrolide therapy is associated with the risk of microbial resistance and cardiovascular adverse effects. Currently, there are no drugs to treat viral infections, such as rhinovirus infections, in COPD.
[0010] There is no treatment available for NCFB. Acute exacerbations of NCFB are generally treated with antibiotics to eliminate the underlying respiratory tract infection. Some patients with NCFB receive prophylactic antibiotic therapy to prevent exacerbations, but the efficacy of such therapy is unproven. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Vestbo et al. (2013) Am J Respir Crit Care Med 187(4):347~65. [Non-Patent Document 2] Flume et al. (2018) Lancet 392(10150): pages 880-90. [Non-Patent Document 3] Chalmers et al. (2018) Am J Respir Crit Care Med 197(11):1410~20. [Non-Patent Document 4] Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 report; Global initiative for chronic obstructive lung disease (GOLD). [Non-Patent Document 5] Mohan A et al. (2010) Respirology 15(3):536~42. [Non-Patent Document 6] Molyneaux et al. (2013) Am J Respir Crit Care Med 188(10):1224~31. [Non-Patent Document 7] Hassett et al. (2014) J Microbiol 52(3):211~26. [Non-Patent Document 8] Miravitlles et al. (2017) Respiratory Research 18:198 pages. [Non-Patent Document 9] Singanayagam et al. (2018) Nature Communications 9(1):2229 pages. Summary of the Invention [Problem to be solved by the invention]
[0012] It is an object of the present invention to provide further and improved treatments for chronic lung diseases, particularly those with infection-related exacerbations such as COPD and NCFB, in particular to prevent or treat acute exacerbations. [Means for solving the problem]
[0013] In contrast to prior art therapies based on antibiotics (optionally in combination with corticosteroids, beta2 agonists and / or anticholinergic bronchodilators) for preventing or treating acute exacerbations, according to the present invention acute exacerbations are prevented or treated by administering a composition comprising polyclonal immunoglobulin to the airways of a human subject.
[0014] Thus, the present invention provides a composition comprising a polyclonal immunoglobulin for use in the prevention or treatment of an acute exacerbation of a chronic lung disease in a human subject, said composition being administered to the airways of the subject.
[0015] The invention also provides a method of preventing or treating an acute exacerbation in a human subject with a chronic lung disease by administering a composition comprising a polyclonal immunoglobulin to the airways of the subject.
[0016] The invention also provides the use of a polyclonal immunoglobulin for the manufacture of a medicament for preventing or treating an acute exacerbation of a chronic lung disease in a human subject, wherein the medicament is administered to the airways of the subject.
[0017] Surprisingly, the application of immunoglobulins to the mucosal epithelium of the airways can reduce inflammation and drive immune elimination of potentially pathogenic microorganisms (e.g. bacteria and / or viruses) present in the mucosal layer, preventing direct damage to the epithelium, e.g. by bacterial extracellular enzymes and toxins, and / or by viral replication (shedding). These effects are advantageous for the prevention or treatment of acute exacerbations that may result, e.g., from bacterial and / or viral airway infections.
[0018] Commercially available immunoglobulin compositions are administered intravenously or subcutaneously, i.e., by systemic administration. Direct local administration to the target airways, for example by aerosol inhalation, can achieve the same exposure to immunoglobulin in the airways, but requires a smaller total dose than required for systemic administration (e.g., intravenously). This local administration directly to the target airway tissue can thereby avoid systemic side effects. Furthermore, administration to the airways can allow the achievement of higher local concentrations than can be achieved by systemic administration, since only a small portion of systemically administered immunoglobulin ends up in the airways.
[0019] Furthermore, intravenous or subcutaneous immunoglobulin therapy is expensive. Direct targeted local administration to the airways provides the same immunoglobulin, e.g., Ig, concentration in the airways as can be achieved by systemic administration. A smaller dose may need to be administered to achieve exposure to G. As a result, administration directly to the airways may be more cost-effective, since less of the composition is needed to achieve the same therapeutic effect in the airways.
[0020] Furthermore, intravenous or subcutaneous immunoglobulin therapy usually requires the attention of a medical professional. For example, intravenous administration requires a nurse or doctor and is usually performed in a clinic. Inhalation of aerosolized immunoglobulin may not require supervision by a medical professional and therefore may be suitable for self-administration at home. As a result, direct administration to the airways may be more practical for the subject, and therefore the subject may be more likely to adhere to the treatment. Improved adherence reduces treatment failure, which may lead to, for example, acute exacerbations and hospitalizations.
[0021] Acute exacerbation The present invention includes the prevention or treatment of acute exacerbations in human subjects with chronic lung disease, typically COPD or NCFB.
[0022] An acute exacerbation is an acute event characterized by a worsening of the patient's respiratory symptoms that exceeds normal day-to-day variation and requires further therapy. Such acute exacerbations can vary in severity.
[0023] In subjects with COPD, mild acute exacerbations require changes in medication for subjects, especially those treated with short-acting bronchodilators (SABDs). Moderate acute exacerbations require medical intervention, especially treatment with SABDs plus antibiotics and / or oral corticosteroids. Severe acute exacerbations require hospitalization or emergency department visits. The subject of the present invention may have mild, moderate or severe acute exacerbations. Typically, the subject has moderate or severe acute exacerbations.
[0024] In subjects with NCFB, acute exacerbations are characterized by worsening of local symptoms (cough, increased sputum volume or change in viscosity, wheezing, shortness of breath, increased sputum purulence with or without increased hemoptysis) and / or general ill health.
[10] Severe acute exacerbations are characterized as requiring unplanned hospitalization or emergency department visit.[3]
[0025] In one embodiment, the composition of the present invention is for use in the prevention of acute exacerbation, i.e., prophylactic therapy.In a particular embodiment, the composition of the present invention is for use in the prevention of acute exacerbation, and the composition prevents and / or treats the established infection in the subject's airway.This prophylactic therapy can prevent viral infection and bacterial infection, and can be particularly effective against bacteria that are resistant to one or more antibiotics.
[0026] Thus, in one embodiment, the compositions of the invention are for use in preventing acute exacerbations, particularly by treating and / or preventing underlying infections of the respiratory tract.Polyclonal immunoglobulins are particularly suitable as they can treat viral and bacterial infections and are effective against bacteria resistant to one or more antibiotics.
[0027] In another embodiment, the composition of the present invention is used in the treatment of acute exacerbations. Typically, acute exacerbations are caused by viral or bacterial infections of the respiratory tract. Polyclonal immunoglobulins recognize a wide range of potentially pathogenic microorganisms (typically bacteria and viruses) in the respiratory tract. Recognition of a wide range of bacteria means that the immunoglobulins are effective in treating bacterial respiratory tract infections, for example, by immune elimination. Recognition of a wide range of viruses means that the immunoglobulins are effective in treating viral respiratory tract infections, for example, by preventing virus binding to host cells, thereby preventing virus replication and excretion. The compositions of the present invention can also be effectively used without the need for diagnostic testing to identify the specific bacterial or viral infection that may be causing or is causing an acute exacerbation, meaning that administration of the composition can begin sooner.
[0028] Treating an acute exacerbation can prevent the acute exacerbation from becoming more severe, for example, treating a mild acute exacerbation can prevent it from progressing to a severe acute exacerbation.
[0029] The composition of the present invention is for use in the treatment or prevention of acute exacerbations. For this treatment or prevention of acute exacerbations, the composition of the present invention is enriched for antibodies that recognize a specific pathogen. In one embodiment, a subject with an acute exacerbation is tested to identify the pathogen (e.g., bacteria and / or virus) that causes the infection underlying the acute exacerbation, and the composition of the present invention is enriched for antibodies specific to the identified pathogen. In one embodiment, the composition of the present invention is enriched by adding a monoclonal antibody specific to the identified pathogen to the composition. In another embodiment, the composition of the present invention is enriched by adding a monoclonal antibody specific to a pathogen that has been identified in the subject's airway. Additionally or alternatively, the composition is enriched for polyclonal immunoglobulins specific to a specific pathogen, obtained, for example, by immunizing a transgenic animal that has been modified to produce human immunoglobulins, or by screening a library of human antibody repertoires for antibodies with specificity for a desired pathogen, and then recombinantly producing the identified antibodies.
[0030] In certain embodiments, the composition is for use in preventing or treating superinfection of the respiratory tract of a subject.Superinfection is a second infection that occurs in the respiratory tract during a first infection of the respiratory tract.In particular, superinfection of the respiratory tract can occur with infection by a second infectious agent that is resistant to the treatment used against the first infectious agent.In one embodiment, both infections are bacterial respiratory tract infections.In another embodiment, the infections include one bacterial respiratory tract infection and one viral respiratory tract infection.
[0031] In one embodiment, the subject of the present invention has a respiratory tract infection caused by bacteria that are resistant to at least one antibiotic.In particular, bacteria may be resistant to multiple antibiotics (multidrug resistance).Polyclonal immunoglobulins recognize many epitopes of bacteria, including epitopes that are not related to antibiotic activity and resistance mechanism, so the composition of the present invention is effective against these resistant bacteria, including multidrug resistant bacteria.
[0032] In one embodiment, the subject of the present invention has respiratory tract infection caused by virus.The composition of the present invention recognizes the virus and treats the infection.In particular, polyclonal immunoglobulin binds to the virus and prevents the virus from binding to its host cell, such as epithelial cells.Polyclonal immunoglobulin prevents the virus from entering the host cell, replicating and discharging.This treatment can be particularly useful because there is no effective antiviral agent for use in treating respiratory tract infection.
[0033] Patient History The subject of the present invention may be a patient with chronic lung disease who has a history of acute exacerbation.
[0034] The rate of acute exacerbations may vary between subjects. The subject of the present invention may have frequent acute exacerbations, for example experiencing two or more acute exacerbations per year. One of the best predictors of subjects with frequent acute exacerbations is a history of acute exacerbations that have been treated before. The composition of the present invention is therefore particularly useful for treating subjects at risk of frequent acute exacerbations, which corresponds to subjects with a history of exacerbations. Thus, in one embodiment, the composition of the present invention is for use in preventing or treating acute exacerbations in a subject, and the subject is pre-preventing or pre-treating. Preferably, the subject has experienced one or more acute exacerbations in the 12 months prior to the prophylaxis or treatment. Preferably, the subject has experienced two or more acute exacerbations in the 12 months prior to the prophylaxis or treatment. In particular, the subject has experienced three or more acute exacerbations in the 12 months prior to the prophylaxis or treatment.
[0035] Maintenance therapy (discussed below) is particularly suitable for such subjects with a history of acute exacerbations.Thus, in certain embodiments, the subject of the present invention has experienced at least one acute exacerbation in the 12 months prior to therapy and is treated with the composition for at least 12 months.
[0036] Specifically, one of the strongest predictors of the frequency of further exacerbations in COPD is the number of exacerbations experienced in the previous year [4]. In particular, subjects with COPD who have experienced two or more exacerbations in the previous year are likely to have frequent exacerbations. Thus, in certain embodiments, the compositions of the present invention are for use in the prevention of an exacerbation in a subject with COPD, the prevention being maintenance therapy of a subject with COPD, the subject having experienced two or more exacerbations in the 12 months prior to starting maintenance therapy, and the maintenance therapy continues for at least 12 months.
[0037] Specifically, in NCFB, one of the strongest predictors of the frequency of further acute exacerbations in patients is the number of acute exacerbations experienced in the previous year [3].In particular, subjects with NCFB who have experienced three or more acute exacerbations in the previous year are likely to have frequent exacerbations.Therefore, in certain embodiments, the composition of the present invention is for use in the prevention of acute exacerbations in subjects with NCFB, where the prevention is the maintenance therapy of subjects with NCFB, where the subject has experienced three or more acute exacerbations in the 12 months prior to the start of maintenance therapy, and the maintenance therapy continues for at least 12 months.
[0038] chronic lung disease The present invention includes the prevention or treatment of acute exacerbations in subjects with chronic lung disease, particularly chronic lung disease where infection is the primary driver of exacerbations, typically COPD and / or NCFB.
[0039] COPD Subjects with COPD typically have a post-bronchodilator FEV1 (forced expiratory volume in 1 second) / FVC (forced vital capacity) ratio of less than 0.7. FEV1 and FVC can be measured by spirometry using methods standard in the art
[11] . As an example, for post-bronchodilator spirometry measurements, spirometry is performed: (i) 10-15 min after a short-acting beta-2 agonist (400 μg) is administered; (ii) 30-45 min after a short-acting anticholinergic (160 μg) is administered; or (iii) 30-45 min after a combination of the two classes of drugs is administered.
[0040] The present invention is particularly suitable for preventing or treating acute exacerbations in subjects with moderate to very severe COPD, i.e. moderate COPD, severe COPD or very severe COPD. Typically, the subject has severe or very severe COPD.
[0041] Such grading of COPD severity is explained in reference [1] and is based on the severity of airflow limitation in a subject. Briefly, in subjects with an FEV1 / FVC ratio <0.7, the grading of the severity of airflow limitation is based on the measured post-bronchodilator FEV1 and how this measurement compares to the predicted value in healthy subjects. Subjects with mild COPD have an FEV1 of at least 80% of the predicted value. Subjects with moderate COPD have an FEV1 of 50%-80% of the predicted value. Subjects with severe COPD have an FEV1 of 30%-50% of the predicted value. Subjects with very severe COPD have an FEV1 of less than 30% of the predicted value.
[0042] The predicted FEV1 for healthy subjects is calculated using the formula
[12] : Male FEV1{liters}=4.30 x height{meters}-0.029 x age{years}-2.49 Female FEV1{liters}=3.95 x height{meters}-0.025 x age{years}-2.60 It is calculated using
[0043] As an example, a male subject aged 50 years and 1.8 m tall would have a predicted FEV1 of 3.8 L (4.3 x 1.8 - 0.029 x 50 - 2.49). If this subject then had a post-bronchodilator FEV1 measured by spirometry of 2.09 L, this would be 55% of the predicted FEV1 (3.8 L) and therefore the subject would be considered to have moderate COPD.
[0044] Moderate to very severe COPD is difficult to treat and even triple therapy (inhaled corticosteroids / beta2 agonists / anticholinergic bronchodilators) is not always successful. The polyclonal immunoglobulins of the present invention are believed to prevent or treat acute exacerbations in subjects with COPD by mechanisms different from those of current treatments, including preventing airway infections and reducing airway inflammation, thus providing an additional and complementary treatment.
[0045] In another embodiment, the composition of the present invention is for use in treating COPD in a subject, and the composition is administered to the airway of the subject. Acute exacerbations contribute to the pathology of COPD and may contribute to the vicious cycle between inflammation and further infection. Prevention of acute exacerbations is therefore a treatment for COPD. Maintenance therapy (discussed below) using the composition of the present invention in a subject with COPD is particularly suitable for treating COPD, as it prevents acute exacerbations (including reducing the occurrence and / or severity of acute exacerbations). For the same reason, seasonal administration of the composition of the present invention is particularly suitable for treating COPD.
[0046] Non-cystic fibrosis bronchiectasis The present invention includes the treatment of acute exacerbations in subjects with chronic lung disease, especially chronic lung disease where infection is the primary driver of exacerbations, typically NCFB. NCFB can have multiple causes and present with a wide range of symptoms. NCFB is characterized by pathological dilation of the airways. In particular, NCFB is defined as a permanent enlargement of the airways, radiographically documented, for example, by computed tomography (CT) scan [2]. Signs of NCFB range from subtle dilation of the airways to cystic changes. Patients may be asymptomatic (and unexpectedly discovered airway dilation) or may have a range of symptoms with periodic exacerbations, such as coughing and / or sputum production.
[0047] The present invention is particularly suitable for preventing or treating acute exacerbations in subjects with NCFB. In one embodiment, the composition of the present invention is for use in preventing or treating acute exacerbations in subjects with NCFB. The composition is particularly suitable for use in preventing severe acute exacerbations in subjects with NCFB. In another embodiment, the composition of the present invention is for use in treating NCFB in a subject, and the composition is administered to the airway of the subject. Acute exacerbations may contribute to the pathology of NCFB and contribute to a vicious cycle between inflammation and further infection. Prevention of acute exacerbations is therefore a treatment for NCFB. Maintenance therapy using the composition of the present invention in subjects with NCFB (discussed below) is particularly suitable for treating NCFB because it prevents acute exacerbations (including reducing the occurrence and / or reducing the severity of acute exacerbations). For the same reason, seasonal administration of the composition of the present invention is particularly suitable for treating NCFB.
[0048] A subject may present with COPD and NCFB as comorbidities. In fact, NCFB is associated with more advanced stages of COPD [2]. Thus, in another embodiment, the composition of the present invention is used to prevent acute exacerbations in subjects with COPD and NCFB. or are particularly suitable for use in therapy.
[0049] Low IgG levels The subject of the present invention may have a level of immunoglobulin G (IgG) lower than the normal range of healthy adults. These subjects are at increased risk of suffering from COPD, have increased severity of COPD, and / or are at increased risk of acute exacerbation of COPD. NCFB is also a common symptom of subjects with immune deficiency, including low levels of IgG.
[0050] IgG in the airways, especially in the lungs, comes from two sources: it is produced locally by plasma cells in the bronchial mucosa, and it is obtained from the plasma by transudation. Thus, subjects of the present invention may have low levels of IgG in the airways, for example due to low systemic levels of IgG and / or low local production of IgG.
[0051] In one embodiment, the subject has a low plasma level of IgG. As presented in reference
[13] , the normal range of plasma total IgG in healthy adults is 639-1,349 mg / dL, with an average of 994 mg / dL. A low level of plasma IgG in an adult can be a level below 700 mg / dL. Lower plasma total IgG levels in adults are classified as mild to moderate (300-600 mg / dL), high (100-300 mg / dL), or severely reduced (less than about 100 mg / dL). In certain embodiments, the subject has a plasma IgG level below about 700 mg / dL, below about 600 mg / dL, below about 300 mg / dL, or below about 100 mg / dL. In some embodiments, the subject has a plasma IgG level in the range of about 100 to about 600 mg / dL (including a range of about 300 to about 600 mg / dL, or about 100 to about 300 mg / dL).
[0052] Various methods for determining plasma total IgG concentration are known in the art, such as rate nephelometry and / or radial immunodiffusion.
[14] Serum IgG can also be quantified by ELISA, for example according to the protocol described in the methods for carrying out the invention below.
[0053] The acute exacerbation that is prevented or treated by the present invention appears in the respiratory tract.Therefore, the local concentration of IgG in the respiratory tract is an important factor in determining the risk of respiratory tract infection, and therefore the risk of acute exacerbation.Subjects whose respiratory tract IgG level is lower than that of healthy adults are at higher risk of respiratory tract infection and acute exacerbation.Therefore, in one embodiment, the subject of the present invention has a lower respiratory tract IgG level than that of healthy adults.
[0054] The level of airway IgG can be measured by analyzing sputum from a subject. Sputum is a mixture of saliva and mucus that is typically expectorated from the airways as a result of an infection or other disease, such as COPD or NCFB. Sputum is often examined under a microscope to aid in medical diagnosis. Sputum can also be analyzed for the content of biomolecules, including immunoglobulins (e.g., IgG, IgA and / or IgM), and cytokines (e.g., IL-1b, IL-6 and / or IL-8). Various methods for determining sputum immunoglobulin concentrations, such as kinetic turbidimetry and / or radial immunodiffusion, are known in the art
[15] . Sputum immunoglobulins can also be quantified by ELISA, for example, following the protocol described in the methods for carrying out the invention below.
[0055] Therapeutic Effects of the Invention Preventing and / or treating respiratory tract infections Respiratory tract infections can be one of the causes of acute exacerbations. Therefore, preventing or treating respiratory tract infections is particularly useful for preventing or treating acute exacerbations. In one embodiment, the composition of the present invention is a method for preventing or treating acute exacerbations in which polyclonal immunoglobulins are delivered to one or more latent antigens in the respiratory tract. The polyclonal immunoglobulins are for use in preventing acute exacerbations, resulting in immune elimination of potentially pathogenic microorganisms (e.g., bacteria and / or viruses) in the respiratory tract. The polyclonal immunoglobulins can provide immune elimination by binding to potentially pathogenic microorganisms in the respiratory tract. For example, the polyclonal immunoglobulins bind to potentially pathogenic microorganisms and prevent them from adhering to the mucosal epithelium of the respiratory tract.
[0056] In another embodiment, the composition of the invention is for use in the prevention or treatment of an acute exacerbation in which the polyclonal immunoglobulin causes one or more potentially pathogenic microorganisms (e.g. bacteria and / or viruses) to aggregate in the respiratory tract. Microbial aggregation is also known as agglutination.
[0057] In another embodiment, the compositions of the invention are for use in the prevention or treatment of acute exacerbations, where the polyclonal immunoglobulins recruit immune cells that kill microorganisms, for example in a process called antibody-dependent cellular cytotoxicity (ADCC).
[0058] Preventing and / or reducing damage caused by respiratory tract infections The activity of microorganisms in the airways of a subject may have pathogenic effects. Thus, in one embodiment, the composition of the present invention is for use in the prevention or treatment of acute exacerbations, where the polyclonal immunoglobulin reduces airway damage caused by pathogens (e.g., bacteria and / or viruses). For example, the polyclonal immunoglobulin can inhibit the activity of extracellular enzymes. Such extracellular enzymes are, for example, enzymes secreted by bacteria into mucous membranes, including enzymes with tissue degrading activity, such as proteases. Blocking the activity of such extracellular enzymes protects the airway epithelium of a subject from damage. In certain embodiments, the composition of the present invention prevents the loss of epithelial barrier integrity and prevents the passage of pathogens across the epithelium. In certain embodiments, the pathogen is a virus, and the polyclonal immunoglobulin binds to the virus and prevents the virus from directly binding to host cells in the airways of a subject. The immunoglobulin therefore prevents the entry, replication and shedding of the virus in the airways of a subject.
[0059] Reduced inflammation Chronic inflammation causes structural changes and narrowing of small airways, contributing to airway injury and remodeling that leads to symptoms of COPD and irreversible dilation of bronchi in NCFB.Increased inflammation and resulting damage can increase the risk of acute exacerbation.The composition of the present invention can reduce inflammation in subjects.Therefore, the composition of the present invention is particularly suitable for use in preventing or treating acute exacerbation in subjects who typically have COPD or NCFB.
[0060] In one embodiment, the composition of the present invention reduces inflammation in a subject, typically local inflammation, such as airway inflammation. In particular, the composition reduces pathogen-induced inflammation, particularly pathogen-induced inflammation in the airway of a subject.
[0061] Inflammation may be characterized by elevated levels of one or more proinflammatory cytokines, such as IL-1b and / or IL-6 and / or IL-8. Thus, in certain embodiments, the compositions of the invention reduce levels of IL-1b and / or IL-6 and / or IL-8, particularly in the mucus layer of the airways.
[0062] The levels of one or more cytokines (e.g., IL-1b and / or IL-6 and / or IL-8 levels) in the mucus layer of the airways can be quantified by analyzing the levels in sputum produced by the subject. Cytokine concentrations in sputum can be quantified according to standard methods, for example, by kinetic nephelometry
[14] or ELISA (e.g., of the methods of the invention described below).
[0063] Polyclonal immunoglobulins The present invention includes the use of polyclonal immunoglobulins for the prevention or treatment of acute exacerbations in subjects with chronic lung disease. Such polyclonal immunoglobulins have been successfully used to treat infectious diseases as replacement therapy in subjects with primary immunodeficiency disorders, as well as to prevent and treat a variety of inflammatory and autoimmune conditions, and certain neurological disorders.
[0064] These polyclonal immunoglobulin preparations were developed for systemic administration and contain mostly IgG. Currently, these preparations are derived from pooled plasma of several thousand healthy donors (1,000-60.000 donors) and contain both specific and natural antibodies reflecting the cumulative antigen experience of the donor population. This large spectrum of specific and natural antibodies can recognize a wide range of antigens (e.g. pathogens, foreign antigens and self / auto antigens).
[0065] Polyclonal immune globulins are generally administered intravenously or subcutaneously, and several commercial preparations are available for these routes of administration.
[0066] The composition of the present invention comprises polyclonal immunoglobulins, also called Ig. Typically, polyclonal immunoglobulins are obtained from human donor plasma. Preferably, the plasma from multiple donors is pooled, for example, from more than 100 donors, preferably more than 500 donors, even more preferably more than 1,000 donors, to maximize the diversity of target antigen specificity.
[0067] Typically, the plasma pool is subjected to an ethanol fractionation step and several subsequent purification steps such as further precipitation and / or column chromatography steps, as well as steps to inactivate and remove viruses and other pathogens such as nanofiltration or solvent / detergent treatment, e.g. methods such as those shown in reference 1.
[0068] Alternatively, polyclonal immunoglobulins are recombinantly produced, eg, from a library containing the human immune repertoire.
[0069] Typically, the polyclonal immunoglobulin is polyclonal IgG, polyclonal monomeric IgA, polyclonal dimeric IgA, polyclonal IgM, or a combination thereof. In a specific embodiment, the composition comprises polyclonal IgG. The polyclonal immunoglobulin may also comprise J-chain-containing IgA and / or IgM combined with secretory component as described in WO2013 / 132052.
[0070] IgG The present invention relates to a composition comprising a polyclonal immunoglobulin for use in the prevention or treatment of acute exacerbations in subjects with chronic lung disease, typically COPD and / or NCFB. Surprisingly, it has been found by the inventors that large immune complexes are formed between IgG and P. aeruginosa. Antigen binding by immunoglobulins is largely dependent on the target antigen binding (Fab) domain. Such an assembly (immune complex) between P. aeruginosa and IgG was unexpected, since IgG is only bivalent with respect to the Fab domain. Thus, in one embodiment, the composition of the invention comprises a polyclonal human plasma-derived IgG. The polyclonal immunoglobulin is at least 95% IgG, preferably at least 98% IgG. The polyclonal IgG is particularly suitable for use in the prevention or treatment of acute exacerbations in subjects with chronic lung disease, typically COPD and / or NCFB, by treating and / or preventing one or more airway infections. is doing.
[0071] One explanation for the unexpected formation of immune complexes between IgG and P. aeruginosa is that IgG may further bind to P. aeruginosa outside the Fab region, possibly through its sugars. IgG may therefore be surprisingly potent at signaling the immune system for P. aeruginosa. As a result, in certain embodiments, the composition of the invention comprising IgG is used to prevent or treat acute exacerbations in subjects with chronic lung disease, typically COPD and / or NCFB, where said subjects have a concurrent P. aeruginosa infection. In another embodiment, the composition of the invention comprising IgG is administered to a subject to prevent P. aeruginosa airway infection. Thus, in a preferred embodiment, the composition of the invention comprising IgG is used to prevent acute exacerbations, and the composition is administered as a maintenance therapy. This composition is particularly useful for maintenance therapy of subjects with chronic lung disease, typically COPD and / or NCFB, since P. aeruginosa is an opportunistic pathogen that can affect subjects with compromised lung defenses, such as COPD or NCFB patients. In particular, P. aeruginosa has been described to be one of the most harmful bacteria found in subjects with COPD and during acute exacerbations of COPD [7].
[0072] Normal human IgG can be obtained with a purity of at least 95% IgG. This means that 95% of polyclonal Ig is IgG. Thus, in one embodiment, the IgG contained in the composition of the present invention generally has a purity of at least 95% IgG, preferably at least 96% IgG, more preferably at least 98% IgG, for example at least 99% IgG.
[0073] Administration of a composition comprising IgA to a subject with selective IgA deficiency may cause the subject to experience anaphylaxis. Anaphylaxis is a severe allergic reaction that often begins suddenly and may lead to the subject's death. Thus, in some embodiments, the compositions of the present invention contain only trace amounts of IgA, for example, less than 200 μg / mL IgA, preferably less than 25 μg / mL IgA. These compositions are particularly suitable for administration to subjects with selective IgA deficiency. Furthermore, selective IgA deficiency does not have severe symptoms, so the subject of the present invention may not be aware that he or she has selective IgA deficiency. Thus, these compositions are particularly useful for administration to subjects who are unaware of whether they have selective IgA deficiency.
[0074] Thus, in a preferred embodiment, the compositions of the invention comprise polyclonal immunoglobulin that is at least 98% IgG and contains less than 25 μg / mL IgA.
[0075] In a particular embodiment, the composition used in the present invention is Pirivigen™. Commercially available immunoglobulin preparations that can also be used in accordance with the present invention include: Bivigam™, Claryg™, Flebogam™ 5%, Flebogamma™ DIF 5%, Gammagard™ liquid 10%, Gammaplex™, Gamunex™ 10%, IG Vena™ N, Intratect™, Kiovig™, Nanogam™, Octagam™, Octagam™ 10%, Polyglobin™ N 10%, Sandoglobulin™ NF liquid, Vigam™, and IQYMUNE™.
[0076] Polyclonal immunoglobulins enriched for specific antibodies The present invention relates to a composition for use in the prevention and / or treatment of acute exacerbations in subjects with chronic lung disease, typically COPD and / or NCFB. As described above, the acute exacerbation may be due to a respiratory tract infection in the subject. In one embodiment, the composition of the present invention The compositions are enriched with one or more antibodies specific for one or more particular pathogens (e.g., bacteria and / or viruses) or potentially pathogenic microorganisms (e.g., bacteria and / or viruses). Such compositions may be particularly useful because they increase the effective dosage of immunoglobulin active against a microorganism or pathogen, and therefore have a greater therapeutic effect or can achieve an equivalent therapeutic effect when a lower total dose of the composition is administered. In one embodiment, the compositions of the invention are enriched with pathogen-specific antibodies by adding pathogen-specific monoclonal antibodies to the composition.
[0077] In one embodiment, the composition of the invention is enriched in antibodies specific to one or more of rhinovirus, influenza A, human metapneumovirus, RSV, coronavirus, influenza B, adenovirus, Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus catarrhalis, Haemophilus parainfluenzae and / or Staphylococcus aureus. Such compositions may be particularly useful since these pathogens are the most common causes of acute exacerbations in subjects with chronic obstructive respiratory disease, typically COPD and / or NCFB. Preferably, the composition of the invention is enriched in antibodies specific to Pseudomonas aeruginosa. It has been described that Pseudomonas aeruginosa is one of the most harmful bacteria found in subjects with COPD and during COPD exacerbations [7]. Preferably, the composition of the invention is enriched in antibodies specific to human rhinovirus, which is the most common viral infection causing acute exacerbations of COPD.
[0078] In one embodiment, a composition of the invention enriched in antibodies specific for a particular pathogen can be obtained by adding a monoclonal Ab or a mixture of two or more monoclonal antibodies specific for one or more pathogens selected from rhinovirus, influenza A, human metapneumovirus, RSV, coronavirus, influenza B, adenovirus, Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus catarrhalis, Haemophilus parainfluenzae and / or Staphylococcus aureus to a composition comprising polyclonal immunoglobulin.
[0079] In one embodiment, a composition of the invention enriched for antibodies specific to a particular pathogen can be obtained by adding polyclonal immunoglobulin obtained from a transgenic animal modified to express human immunoglobulins after immunization with a particular pathogen to a composition comprising polyclonal immunoglobulin.
[0080] In one embodiment, a composition of the invention enriched for antibodies specific to a particular pathogen can be obtained by adding to a composition comprising polyclonal immunoglobulins several specific immunoglobulins obtained by screening a library of human antigen binding sites with a particular pathogen or antigens derived from a particular pathogen, and recombinantly producing pathogen-specific immunoglobulins having these antigen binding sites.
[0081] IgA and IgM In one embodiment, the composition of the present invention comprises IgA and / or IgM. In a particular embodiment, at least 95% by weight of the polyclonal immunoglobulin is IgA and / or IgM. The IgA and / or IgM are combined with recombinant secretory components to construct secretory antibodies. In a particular embodiment, the composition comprises IgA and IgM in a mass ratio of about 2:1.
[0082] Preferably, the IgA and / or IgM are prepared from plasma, for example as described in detail in WO2013 / 132053.
[0083] The composition preferably used in the present invention is prepared as described in detail in WO2013 / 132053.Preferably, the plasma-derived preparation containing IgA and / or IgM is combined with SC in vitro without the need for prior purification of dimeric / multimeric J-chain-containing IgA / IgM. Such material is called secretory-like IgA or secretory-like IgM, or abbreviated as SCIgA or SCIgM. However, this material behaves more similarly to in vivo produced secretory IgA (usually abbreviated SIgA) and in vivo produced secretory IgM (usually abbreviated SIgM).
[0084] In one embodiment, the composition comprises polyclonal human plasma-derived multimeric IgA and IgM. In a preferred embodiment, the IgA and IgM are assembled into secretory antibodies by combination with recombinant secretory component (SC). Preferably, the composition comprises IgA and IgM in a 2:1 mass ratio.
[0085] In another particular embodiment, the composition comprises IgA with a purity of at least 90%, preferably at least 92%, more preferably at least 94%, even more preferably at least 96%, and most preferably at least 98%. Preferably, the IgA is purified from human plasma; however, other sources of IgA, such as milk, saliva, or other IgA-containing body fluids, can also be used. In another particular embodiment, the IgA is monomeric IgA. In yet another particular embodiment, the IgA is enriched for dimeric IgA, which also includes J chain; preferably at least 20%, more preferably at least 30%, even more preferably at least 40%, and most preferably at least 50% of the IgA is in dimeric form. Optionally, the IgA composition may further comprise a secretory component (SC), preferably a recombinantly produced secretory component. For example, the compositions disclosed in WO2013 / 132052, the entirety of which is incorporated by reference, are used.
[0086] In yet another specific embodiment, the composition comprises IgM. In one embodiment, the composition comprises IgM and IgA. In a preferred embodiment, the composition comprises IgM and dimeric IgA, and also comprises a J chain. Optionally, the composition may also comprise a secretory component, preferably a recombinantly produced secretory component. In yet another embodiment, the composition comprises IgM, IgA and IgG. In a specific embodiment, such a composition may contain 76% IgG, 12% IgA and 12% IgM.
[0087] The IgA and / or IgM are produced from human plasma. Preferably, the IgA and / or IgM are combined in vitro with secretory component (SC). More preferably, the SC is a human secretory component. Even more preferably, the SC is a recombinant SC expressed in a mammalian cell line.
[0088] Preferably at least 10% of the proteins in the composition are SCIgA (IgA in combination with SC), more preferably at least 15%, 18%, 20%, or 25%, even more preferably at least 30%, 40% or 50% of the proteins in the composition are SCIgA. Preferably at least 10% of the proteins in the composition are SCIgM (IgM in combination with SC), more preferably at least 15%, 18%, 20% or 25%, even more preferably at least 30%, 40% or 50% of the proteins in the composition are SCIgM.
[0089] Preferably, at least 10% of the proteins in the composition are SCIgA and at least 10% of the proteins in the composition are SCIgM, more preferably, at least 15% are SCIgA and at least 15% are SCIgM, even more preferably, at least 20% are SCIgA and at least 20% are SCIgM.
[0090] aerosol The present invention relates to a composition comprising polyclonal immunoglobulin for use in the treatment or prevention of acute exacerbations in patients with chronic lung disease, particularly COPD and / or NCFB, wherein the composition is administered to the airways of the subject. Typically, the composition of the present invention is administered to the airways of the subject as an aerosol. The aerosol is generated by nebulizing a composition comprising liquid aqueous polyclonal immunoglobulin. Alternatively, the aerosol may be a dry powder aerosol, for example produced by a dry powder inhalation system
[17] . Alternatively, a soft mist inhaler, aqueous droplet inhaler, or pressurized metered dose inhaler, or any other device suitable for delivering immunoglobulin to the airways of a patient is used.
[0091] liquid aqueous composition Liquid aqueous compositions are particularly suitable for nebulization to form aerosols that are administered to the respiratory tract of subjects.Therefore, the compositions of the present invention are generally in liquid aqueous form.Liquid aqueous compositions are liquid systems in which the liquid carrier or solvent is mainly or completely composed of water.In certain cases, liquid carriers can contain a small fraction of one or more liquids that are at least partially miscible with water.
[0092] The present invention relates to the administration of the compositions of the present invention to the respiratory tract of a subject. For such administration to the respiratory tract, it is preferable to use high concentration polyclonal immunoglobulin. Generally, high doses of polyclonal immunoglobulin are useful for increasing efficacy, but it is also useful to minimize the administered volume, for example, when administered by a nebulizer, to keep the nebulization time as short as possible. Keeping the nebulization time as short as possible is particularly useful for maintaining subject compliance. Thus, in one embodiment, the compositions of the present invention have a high concentration of polyclonal immunoglobulin, for example, about 20 to about 200 mg / mL. The concentration of polyclonal immunoglobulin may range from 20-190 mg / mL, 20-180 mg / mL, 20-170 mg / mL, 20-160 mg / mL, 20-150 mg / mL, 30-200 mg / mL, 30-190 mg / mL, 30-180 mg / mL, 30-170 mg / mL, 30-160 mg / mL, 30-150 mg / mL, 40-200 mg / mL, 40-190 mg / mL, 40-180 mg / mL, 40-170 mg / mL, 40-160 mg / mL, 40-150 mg / mL. Suitable polyclonal immunoglobulin concentrations for the compositions of the invention range from 20 to 140 mg / mL, 20 to 130 mg / mL, 20 to 120 mg / mL, 30 to 140 mg / mL, 30 to 130 mg / mL, 30 to 120 mg / mL, 40 to 140 mg / mL, 40 to 130 mg / mL, 40 to 120 mg / mL, 50 to 140 mg / mL, 50 to 130 mg / mL or 50 to 120 mg / mL; in particular, the polyclonal immunoglobulin concentration is about 50 mg / mL, about 60 mg / mL, about 70 mg / mL, about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, or about 120 mg / mL.
[0093] A relatively high concentration allows for low loading volumes and short nebulization times, which is therefore important for ensuring therapeutic efficacy of the treatment. In certain preferred embodiments, the composition comprises polyclonal IgG at a concentration of about 50 mg / mL to about 100 mg / mL. Most preferably, the composition comprises polyclonal IgG at a concentration of about 100 mg / mL.
[0094] Typically, the liquid aqueous composition of the present invention contains one or more stabilizers. A problem commonly encountered when formulating liquid immunoglobulin preparations is that immunoglobulins tend to form aggregates and precipitates if not sufficiently stabilized with appropriate additives. Thus, in one embodiment, the composition of the present invention contains a stabilizer, for example, amino acids such as proline, glycine and histidine, or saccharides, or sugar alcohols, or proteins such as albumin, or combinations thereof. These Each of the additives is known to stabilize immunoglobulins in liquid aqueous formulations and is used in the liquid aqueous compositions of the invention. In certain embodiments, the compositions of the invention include a stabilizer, and the stabilizer is proline, glycine or histidine, preferably proline.
[0095] Increasing immunoglobulin concentration in liquid aqueous composition leads to non-linear increase in viscosity. As disclosed in WO2011 / 095543, proline has been found to be particularly suitable as a stabilizer, since a relatively low viscosity of the composition of the present invention is achieved even at high polyclonal immunoglobulin concentrations, so that spraying problems caused by high viscosity can be avoided. On the one hand, proline provides the desired stability of polyclonal immunoglobulin in liquid aqueous composition, and on the other hand, it reduces the viscosity of the composition, thus allowing spraying of small liquid volumes at high polyclonal immunoglobulin concentrations, resulting in rapid and effective treatment by spraying. Therefore, in a particular embodiment, the composition of the present invention comprises proline, especially when the composition of the present invention is in liquid aqueous form.
[0096] L-proline is normally present in the human body and has a very favorable toxicity profile, so it is particularly suitable for use in the composition of the present invention.The safety of L-proline has been investigated in repeated dose toxicity test, reproductive toxicity test, mutagenicity test and safety pharmacology test, and no adverse effects have been found.Therefore, in a preferred embodiment, the composition of the present invention comprises L-proline.
[0097] In general, the composition of the present invention contains proline, preferably L-proline, in the range of about 10 to about 1000 mmol / L, for example about 100 to about 500 mmol / L, in particular about 250 mmol / L.
[0098] In a preferred embodiment, the composition of the present invention contains about 210-290 mmol / L L-proline, in particular 250 mmol / L L-proline. In a specific embodiment, the composition comprises polyclonal IgG and about 250 mmol / L L-proline.
[0099] In one embodiment, the viscosity of a liquid aqueous composition of the invention comprising polyclonal immunoglobulin and proline ranges from 1 mPa-s to 17 mPa-s (at a temperature of 20.0° C.+ / -0.1° C.). In a particular embodiment, the viscosity of a composition comprising 100 mg / mL polyclonal IgG and 250 mmol / L L-proline is about 3 mPa-s at a temperature of 20.0° C.+ / -0.1° C.
[0100] Typically, compositions of the invention comprising polyclonal IgG and containing proline have a pH of 4.2 to 5.4, preferably 4.6 to 5.0, and most preferably about 4.8, which further contributes to high stability of the preparation.
[0101] The use of proline allows for the preparation of compositions that use one single agent to improve the stability of the formulation and reduce the viscosity of the composition, resulting in a composition that is particularly useful in methods of generating aerosols with mesh nebulizers.
[0102] The compositions of the invention usually include components in addition to the polyclonal immunoglobulin. For example, the compositions typically include one or more additional pharmaceutical carriers and / or excipients. A discussion of such components is available in reference 2.
[0103] In one embodiment, the compositions of the invention also include pharma- ceutically acceptable excipients that serve to optimize the composition and / or aerosol properties. Examples of such excipients include excipients for adjusting or buffering pH, excipients for adjusting osmolality, antioxidants, and the like. These excipients are surfactants, excipients for sustained release or sustained local retention, taste masking agents, sweeteners, and flavors. These excipients are used to obtain optimal pH, osmolality, viscosity, surface tension, and taste that support formulation stability, aerosolization of the formulation upon inhalation, tolerability, and / or efficacy.
[0104] The liquid aqueous compositions of the present invention typically have a surface tension of about 60-75 mM / m, preferably about 64-71 mM / m. Surfactants are added to the compositions of the present invention. These may help to control the rate of aggregation of polyclonal immunoglobulins in the composition (i.e., during storage and in the reservoir) and during aerosolization (i.e., during and after passage through the mesh of the nebulizer), thereby affecting the activity of polyclonal immunoglobulins in the aerosol. Thus, in one embodiment, the compositions of the present invention are liquid aqueous compositions that include a surfactant, for example, a polysorbate such as polysorbate 80.
[0105] spray The present invention involves administration of a composition to the respiratory tract of a subject. The composition of the present invention is administered to the respiratory tract of a subject as an aerosol produced by spraying a liquid aqueous composition of the present invention using a nebulizer.
[0106] A nebulizer is a device that can aerosolize a liquid substance into a dispersed liquid phase. An aerosol is a system that contains a continuous gas phase and, dispersed therein, a discontinuous or dispersed phase of solid or liquid particles (typically liquid particles when produced by atomization of a liquid aqueous composition).
[0107] The liquid aqueous composition of the present invention is nebulized by mesh nebulizer or ultrasonic nebulizer or jet nebulizer, or any other device that can nebulize the composition of the present invention.In one embodiment, mesh nebulizer is used to generate aerosol for administering to subject.For example, mesh nebulizer and generated aerosol are used as disclosed in WO2015 / 150510, the entirety of which is incorporated herein by reference.
[0108] The dispersed liquid phase (aerosol) is essentially composed of droplets. The dispersed phase droplets contain polyclonal Ig, such as IgG, IgA, IgM or combinations thereof, in a liquid environment. The liquid environment is a predominantly aqueous phase, with or without additional excipients, as further described below. It will be understood by those skilled in the art that the characteristics and preferences disclosed herein regarding the liquid composition also apply to the dispersed phase of the aerosol generated therefrom, and vice versa.
[0109] Two values have been experimentally determined and can be useful to describe the particle or droplet size of the aerosol generated: the mass median diameter (MMD) and the mass median aerodynamic diameter (MMAD). The difference between the two values is that the MMAD is normalized to the density of water (equivalent aerodynamic).
[0110] MMAD is measured by an impactor, such as an Andersen Cascade Impactor (ACI) or a Next Generation Impactor (NGI). Alternatively, laser diffraction methods, such as the Malvern MasterSizer X™, are used to measure MMD.
[0111] The dispersed phase of the aerosol produced by the method of the present invention typically exhibits a particle size, e.g., MMD, preferably less than 10 μm, preferably from about 1 to about 6 μm, more preferably from about 1.5 to about 5 μm, even more preferably from about 2 to about 4.5 μm. Alternatively, the particle size is preferably The MMAD may be less than 10 μm, preferably between about 1 and about 6 μm, more preferably between about 1.5 and about 5 μm, and even more preferably between about 2 and about 4.5 μm. Another parameter describing the dispersed phase of an aerosol is the particle size distribution of the aerosolized liquid particles or droplets. The geometric standard deviation (GSD) is an often used measure of the spread of the particle size or droplet size distribution of the generated aerosol particles or droplets. The selection of the exact MMD within the above range should take into account the target area or tissue of deposition of the aerosol. For example, the optimal droplet size will vary depending on whether oral, nasal or tracheal inhalation is intended, and whether the focus is on upper and / or lower airway delivery (e.g., to the oropharynx, pharynx, trachea, bronchi, alveoli, lungs, nose, and / or sinuses). Additionally, age-dependent anatomical geometry (e.g., geometry of the nose, mouth or respiratory tract) as well as respiratory diseases and conditions of the subject and the breathing patterns of the subject are among the important factors that determine the optimal particle size (e.g., MMD and GSD) for drug delivery to the lower or upper respiratory tract.
[0112] Generally, small airways, defined by an internal diameter smaller than 2 mm, represent nearly 99% of lung volume and therefore play a key role in lung function. Alveoli are the deep lung sites where oxygen and carbon dioxide are exchanged with blood. Inflammation of alveoli induced by some viruses or bacteria leads to in situ fluid secretion, directly affecting the oxygen intake by the lung. Therapeutic targeting of deep lung airways using aerosols requires aerosols with MMD below 5.0 μm, preferably below 4.0 μm, more preferably below 3.5 μm, even more preferably below 3.0 μm. Such MMD values are therefore envisaged for use in the present invention.
[0113] For aerosol delivery to the respiratory tract, the aerosol has an MMD below 10.0 μm, preferably below 5.0 μm, more preferably below 3.3 μm, even more preferably below 2.0 μm. Preferably, the MMD (droplet diameter) is in the range of about 1.0 to about 5.0 μm, with a size distribution having a GSD of less than 2.2, preferably less than 2.0, more preferably less than 1.8, or even more preferably less than 1.6. Such particle size and particle size distribution parameters are particularly useful for achieving high local drug concentrations in the human respiratory tract (e.g., lungs), including the bronchi and bronchioles, relative to the amount of drug aerosolized. In this context, it must be considered that deep lung deposition requires a smaller MMD than deposition in the central airways of adults and children, with even smaller droplet sizes (MMD's) in the range of about 1.0 to about 3.3 μm being more preferred for infants and young children, with a range below 2.0 μm being even more preferred. Therefore, in aerosol therapy, it is common to evaluate the fraction of droplets smaller than 5 μm (corresponding to the fraction suitable for respiration by adults) and smaller than 3.3 μm (corresponding to the fraction suitable for respiration by children or the fraction deposited in the deeper lungs of adults).Fraction of droplets smaller than 2 μm is also often evaluated, because it corresponds to the fraction of aerosol that can optimally reach the terminal bronchioles and alveoli of adults and children and can penetrate the lungs of infants and young children.
[0114] In the present invention, the fraction of droplets having a particle size smaller than 5 μm is preferably greater than 65%, more preferably greater than 70%, even more preferably greater than 80%. The fraction of droplets having a particle size smaller than 3.3 μm is preferably greater than 25%, more preferably greater than 30%, even more preferably greater than 35%, even more preferably greater than 40%. The fraction of droplets having a particle size smaller than 2 μm is preferably greater than 4%, more preferably greater than 6%, even more preferably greater than 8%.
[0115] The aerosol may also be characterized by its delivered dose (DD), which is determined in simulated breath experiments. The delivered dose may be measured using laser diffraction (e.g., Malvern MasterSizer X™) or using an impactor (e.g., Andersen Cascade Impactor - ACI, or Next Generation Impactor - NGI). The respirable dose (RD) is calculated based on the reactive fraction (RF) of the inhaled air. When the method of the present invention is applied in a breathing simulation experiment (using, for example, a breathing simulator such as Copley's BRS3000 or PARI's Compass II™) with an adult breathing pattern (sinusoidal flow, 500 mL tidal volume, 15 breaths / min) and 2 mL of the composition (e.g., 200 mg Ig, 200 mg IgG, 200 mg IgA, 200 mg IgM or combinations thereof) is loaded into a mesh nebulizer, the delivered dose (DD) is preferably higher than 40% (80 mg Ig, e.g., IgG, IgA, IgM or combinations thereof), more preferably higher than 45% (90 mg Ig, e.g., IgG, IgA, IgM or combinations thereof), even more preferably higher than 50% (100 mg Ig, e.g., IgG, IgA, IgM or combinations thereof). Ig, e.g., IgG, IgA, IgM or a combination thereof).
[0116] For treatment of the upper respiratory tract, particularly the nose, the nasal and / or paranasal sinus mucosa, the osteomeatal complex, and the paranasal sinuses, an MMD of below about 5.0 μm, or below about 4.5 μm, or below about 4.0 μm, or below about 3.3 μm or below about 3.0 μm is particularly suitable.
[0117] The suitability of the generated aerosols for application to the upper airways can be evaluated in nasal inhalation models, such as the human nose model described in WO2009 / 027095. For nasal aerosol delivery, there are, for example, the Sinus™ device (jet nebulizer) from PARI and also mesh nebulizers (prototype of Vibrent™ technology).
[0118] The nebulizer used in the present invention may be a mesh nebulizer. Preferably, the mesh nebulizer is a vibrating membrane nebulizer. The latter type of nebulizer includes a reservoir filled with the liquid to be nebulized. When the nebulizer is operated, the liquid is sent to a mesh that is made to oscillate, i.e. vibrate (e.g., by a piezoelectric element). The liquid present on one side of the vibrating mesh is thereby transported through the openings (also called "pores" or "holes") of the vibrating mesh and takes the form of an aerosol on the other side of the vibrating mesh (e.g., eFlow High Speed and eRapid by PARI, HL100 by Health and Life, and AeronebGo and AeronebSolo by Aerogen). Such nebulizers are called "active membrane nebulizers".
[0119] In other useful mesh nebulizers, the composition is nebulized by vibrating the liquid rather than the membrane. Such oscillating fluid mesh nebulizers include a reservoir filled with the liquid to be nebulized. When the nebulizer is operated, the liquid is delivered to the membrane by a delivery system that is made to oscillate (i.e., vibrate, for example, by a piezoelectric element). The delivery system can be a vibrating back wall of the reservoir (e.g., AerovectRx™ Technology, Pfeifer Technology) or a vibrating liquid delivery slider (e.g., Respironics' I-Neb™ device, or Omron's U22™ device). These nebulizers are called "passive mesh nebulizers."
[0120] Different membrane types are available for the atomization of liquids by mesh nebulizers. These membranes are characterized by different pore sizes that generate aerosols with different droplet sizes (MMD and GSD). Depending on the characteristics of the composition and the desired aerosol properties, different membrane types (i.e., different modified mesh nebulizers or aerosol generators) are used. In the present invention, the MMD is in the range of 2.0 μm to 5.0 μm, preferably 3.0 μm to 5.0 μm. It is preferred to use a membrane type that generates an aerosol with an MMD in the range of 4.9 μm, more preferably in the range of 3.4 μm to 4.5 μm. In another embodiment of the invention, it is preferred to use a membrane type that is integrated into an aerosol generator device that generates an aerosol with an MMD in the range of 2.8 μm to 5.5 μm, preferably in the range of 3.3 μm to 5.0 μm, more preferably in the range of 3.3 μm to 4.4 μm, such as isotonic saline (NaCI 0.9%). In another embodiment of the invention, it is preferred to use a membrane type that is integrated into an aerosol generator device that generates an aerosol with an MMD in the range of 2.8 μm to 5.5 μm, preferably in the range of 2.9 μm to 5.0 μm, more preferably in the range of 3.8 μm to 5.0 μm, such as isotonic saline.
[0121] When the treatment is intended to target the lower airways such as bronchi or deep lung, it is particularly preferred to select piezoelectric perforated mesh nebulizer for generating aerosol.The examples of suitable nebulizers include passive mesh nebulizers such as I-Neb (trademark), U22 (trademark), U1 (trademark), Micro Air (trademark), ultrasonic nebulizers such as Multisonic (trademark), and / or passive mesh nebulizers such as HL100 (trademark), Respimate (trademark), eFlow (trademark) Technology nebulizers, AeroNeb (trademark), AeroNeb Pro (trademark), AeronebGo (trademark) and AeroDose (trademark) device family, and prototype Pfeifer, Chrysalis (Philip Morris) or AerovectRx (trademark) device. Particularly preferred nebulizers for targeting drugs to the lower airways are vibrating perforated membrane nebulizers or so-called active mesh nebulizers, such as eFlow™ nebulizers (electronic vibrating membrane nebulizers available from PARI, Germany).Alternatively, passive mesh nebulizers are used, such as U22™ or U1™ from Omron, or nebulizers based on Telemaq.fr technology or Ing. Erich Pfeiffer GmbH technology.
[0122] A preferred mesh nebulizer for targeting the upper airways is a nebulizer that generates aerosol by a perforated vibrating membrane principle, such as a modified investigational membrane nebulizer using eFlow™ technology, which can also eject a pulsating airflow, so that the generated aerosol cloud pulsates (i.e., undergoes pressure fluctuations) at the desired location or during transport of the aerosol cloud to the desired location (e.g., sinonasal sinus or paranasal sinus). This type of nebulizer has a nosepiece to direct the flow that transports the aerosol cloud to the nose. Aerosol delivered by such modified electronic nebulizers is much better at targeting the sinonasal sinuses than when the aerosol is delivered in a continuous (non-pulsating) mode. The pulsating pressure waves can reach the paranasal cavities, paranasal sinuses, and paranasal sinuses. The aerosols applied at the same time are better distributed and deposited in these cavities because the pulsating pressure waves achieve a more intensive ventilation of the paranasal sinuses.
[0123] More specifically, a preferred nebulizer for targeting the upper respiratory tract of a subject is one suitable for generating an aerosol at an effective flow rate of less than about 5 liters / min while operating a means for producing pressure pulsations of the aerosol at a frequency in the range of about 10 to about 90 Hz, the effective flow rate being the flow rate of the aerosol as it enters the respiratory system of the subject. Examples of such electronic nebulizers are disclosed in WO2009 / 027095.
[0124] In a preferred embodiment of the invention, the nebulizer for targeting the upper airways is a nebulizer that uses a transport flow that is interrupted when the aerosol cloud reaches the desired location and then starts pulsating the aerosol cloud, for example in an alternating mode. 097119 and WO2011 / 134940.
[0125] Whether suitable for pulmonary or sinus delivery, the nebulizer should preferably be selected or adapted to be able to aerosolize a unit dose at a preferred output rate. A unit dose is defined herein as the volume of liquid aqueous composition containing an effective amount of active compound, i.e., Ig, IgG, IgA, IgM, or combinations thereof, designated to be administered during a single administration. Preferably, the nebulizer can deliver such a unit dose at a rate of at least 0.1 mL / min, or at a rate of at least 100 mg / min, assuming that the relative density of the composition is usually approximately 1. More preferably, the nebulizer can generate an output rate of at least 0.4 mL / min or 400 mg / min, respectively. In a further embodiment, the liquid output rate of the nebulizer or aerosol generator is at least 0.50 mL / min, preferably at least 0.55 mL / min, more preferably at least 0.60 mL / min, even more preferably at least 0.65 mL / min, and most preferably at least 0.7 mL / min, and such devices, referred to as aerosol generators, have a high output or high output rate. Preferably, the liquid output rate ranges from about 0.35 to about 1.0 mL / min or from about 350 to about 1000 mg / min; preferably, the liquid output rate ranges from about 0.5 to about 0.90 mL / min or from about 500 to about 800 mg / min. Liquid output rate refers to the amount of liquid composition nebulized per time unit. The liquid may contain an active compound, a drug, Ig, IgG, IgA, IgM or combinations thereof and / or substitutes such as sodium chloride 0.9%.
[0126] The discharge rate of the nebulizer should typically be selected to achieve a short nebulization time of the liquid composition. Obviously, the nebulization time will depend on the volume of the composition to be aerosolized, and the discharge rate. Preferably, the nebulizer should be selected or adapted to be able to aerosolize a volume of liquid composition containing an effective dose of polyclonal Ig, e.g., IgG, IgA, IgM, or a combination thereof, within 20 minutes. More preferably, the nebulization time of a unit dose is 15 minutes or less. In a further embodiment, the nebulizer is selected or adapted to allow a nebulization time per unit dose of 10 minutes or less, more preferably 6 minutes or less, and even more preferably 3 minutes or less. Currently most preferred is a nebulization time in the range of 0.5 to 5 minutes.
[0127] The volume of the composition nebulized according to the invention is preferably low to allow short nebulization times. The volume, also called the dose volume, or the dose unit volume, or the unit dose volume, should be understood as the volume intended to be used for one administration or nebulizer therapy session. Specifically, the volume may range from 0.3 mL to 6.0 mL, preferably from 0.5 mL to 4.0 mL, or more preferably from 1.0 mL to about 3.0 mL, or even more preferably about 2.0 mL. In cases where a residual volume is desired or useful, this residual volume should be less than 1.0 mL, more preferably less than 0.5 mL, and most preferably less than 0.3 mL. The effective nebulization volume is then preferably in the range of 0.2 to 3.0 mL or 0.5 to 2.5 mL, or more preferably in the range of 0.75 to 2.5 mL or 1.0 to 2.5 mL.
[0128] Preferably, the nebulizer is adapted to generate an aerosol in which a major fraction of the loaded dose of the liquid composition is delivered as an aerosol, i.e., to have a high output. More specifically, the nebulizer is adapted to generate an aerosol that contains at least 50% of the dose of Ig, e.g., IgG, IgA, IgM, or a combination thereof, in the composition, or, in other words, to eject at least 50% of the liquid composition loaded in the reservoir. It is important to select a nebulizer that can generate such a high output of polyclonal Ig, e.g., IgG, IgA, IgM, or a combination thereof, especially compared to monoclonal antibodies, whose dose does not need to be as high due to their specificity. It has been found that the mesh nebulizers used in the methods of the invention are capable of producing aerosols of polyclonal Ig, such as IgG, IgA, IgM, or combinations thereof, in compositions with particularly high output.
[0129] dry powder inhalation The composition of the present invention can also be dry powder.Various forms of dry powder inhalers are available, such as capsule dry powder inhalers and multi-dose dry powder inhalers, single dose forms such as rotary inhalers, multi-dose forms such as Accuhaler inhalers and disk inhalers.Dry powder inhalers can be advantageous by providing an easy-to-use, rapid inhalation system suitable for more frequent use.
[0130] dosage The compositions of the invention are for use in the prevention or treatment of an acute exacerbation.
[0131] In one embodiment, the composition of the present invention is for use in preventing acute exacerbation of subjects with chronic lung disease (typically COPD or NCFB), and the composition is administered as maintenance therapy.Maintenance therapy means that once therapy is started, subject continues therapy for a long period of time.For example, therapy lasts for at least 6 months.Typically, therapy lasts for at least 1 year.
[0132] The compositions of the present invention are typically administered to the respiratory tract of a subject as an aerosol, in particular, the aerosol is generated from a liquid aqueous composition using a nebulizer. Suitable liquid aqueous compositions are described above. In a preferred embodiment, the liquid aqueous composition has a polyclonal immunoglobulin (e.g., IgG, IgA, IgM, or a combination thereof) concentration of about 50 mg / mL to about 150 mg / mL, for example about 100 mg / mL.
[0133] For administration to the respiratory tract of a subject of the present invention, the liquid aqueous composition used to generate the aerosol is administered in a volume of 2 to 10 mL.
[0134] For use in treating or preventing (typically preventing) acute exacerbations, such as acute exacerbations of COPD or NCFB, the composition is administered once every 48 hours, once every 24 hours, or once every 12 hours during therapy. In certain embodiments, the composition of the present invention is administered once every 12 hours. In certain embodiments, the composition of the present invention is administered every 24 hours. In certain embodiments, the composition of the present invention is administered every 48 hours.
[0135] For use in the prevention or treatment (typically prevention) of acute exacerbations, such as acute exacerbations of COPD or NCFB, a dose of about 0.01 g to about 1.5 g of polyclonal immunoglobulin is used. A particularly suitable dose of the composition of the invention is a dose of about 0.1 g to about 1.5 g of polyclonal immunoglobulin, such as about 0.2 g to about 1 g, in particular, the dose is about 0.2 g. In a particular embodiment, a dose of about 0.2 g is administered once a day.
[0136] Such doses can be adjusted depending on factors that may increase the risk of acute exacerbations, such as the risk of respiratory tract infections. By way of example, the dose and / or frequency of administration according to the invention is increased in autumn and winter, especially in winter.
[0137] In another embodiment, aerosol is generated from dry composition using dry powder inhaler.Typically, the dose delivered in one administration can be relatively low, such as about 0.5mg, but subject can use multiple inhalations per day, for example 1 to about 20 inhalations per day, preferably 2 to about 15 inhalations per day.
[0138] Seasonal administration The therapy (prevention or treatment) of the present invention is particularly useful during colder weather, which is associated with increased rates of respiratory tract infections and acute exacerbations in subjects with chronic lung disease, typically COPD and / or NCFB. In one embodiment, the composition is administered in autumn and / or winter. In particular, the composition is administered in winter. The occurrence of acute exacerbations of COPD shows seasonal variation, with higher rates in autumn and winter
[19] . This increase in acute exacerbations may be due to an increase in the rate of respiratory tract infections, such as rhinovirus infections. Thus, administering the composition in autumn and winter provides protection against such infections during periods of increased risk.
[0139] Such seasonal variations are likely to affect all subjects with COPD, and therefore this seasonal dosing, for example in the fall and winter, particularly in the winter, is useful for any subject with COPD as characterized herein. The similarities between COPD and NCFB, particularly acute exacerbations that may result from airway infections, suggest that such seasonal dosing is likely to be useful for subjects with NCFB.
[0140] As used herein, the term "autumn" refers to the months commonly recognized as occurring during the fall or autumn. In the Northern Hemisphere, these months include September, October, and November. In the Southern Hemisphere, these months include March, April, and May.
[0141] As used herein, the term "winter" refers to the months commonly recognized as occurring during the winter. In the Northern Hemisphere, these months include October, November, December, January, and February. In the Southern Hemisphere, these months include April, May, June, July, and August.
[0142] Combination therapy with antibiotics The polyclonal immunoglobulins of the invention are particularly suitable for administration in combination with antibiotics, for example to prevent or treat bacterial airway infections in subjects with chronic lung disease, typically COPD and / or NCFB.
[0143] In one embodiment, the compositions of the invention are administered in conjunction with antibiotics during the acute phase of a bacterial infection while the subject is undergoing antibiotic therapy, i.e., the compositions are administered during the first 2 days, particularly the first 3 days, first 4 days, or first 5 days of infection, in addition to standard antibiotic therapy.
[0144] General The term "comprising" encompasses "including" and "consisting." For example, a composition "comprising" X may consist of only X, or it may include something additional, e.g., X+Y. The word "substantially" does not exclude "completely." For example, a composition "substantially free" of Y may be completely free of Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
[0145] The term "about" in connection with a numerical value x is optional and means, for example, x±10%. The compositions of the invention are compositions that include polyclonal immunoglobulins, and unless specifically stated otherwise, the effects attributable to the composition are mediated by the polyclonal immunoglobulins and not by any unspecified additional components.
[0146] Unless specifically stated, a process that includes mixing two or more components does not require any particular order of mixing. Thus, the components can be mixed in any order. Where there are three components, two components may be combined with each other and then the combination may be mixed in a first order. It is combined with ingredients 3, etc.
[0147] The invention will now be illustrated in the following non-limiting examples with reference to the following figures. [Brief description of the drawings]
[0148] [Figure 1] 1 shows that plasma-derived Ab preparations interact with Pseudomonas aeruginosa (PA). Binding of increasing concentrations of plasma-derived Ab or secretory IgA / M to coated PA as determined by ELISA. [Diagram 2] Figure 2: Conjugation of plasma-derived IgG preparations with PA promotes aggregation. Laser scanning confocal microscopy images of immune complexes of PA conjugated with plasma-derived IgG. Bacteria were labeled with CFSE and IgG with Cy3 dye. Images are representative of one observation field from 5-10 observations from two independent slides. [Diagram 3] Figure 1 shows plasma-derived immunoglobulin preparation PA-induced LDH tissue release. Tissue damage was assessed by measuring LDH release in MucilAir™ basal medium. Non-infected transwells receiving vehicle alone or plasma-derived immunoglobulin preparation served as controls. PA-infected transwells served as positive controls. Data are representative of three independent experiments. [Figure 4] FIG. 1 shows that plasma-derived IgG formulations dose-dependently prevent the loss of transepithelial electrical resistance. Tissue integrity was assessed measuring transepithelial electrical resistance. Non-infected and proline-treated transwells served as negative controls, and PA-infected transwells served as a positive control for tissue damage. Data are representative of three independent experiments. [Diagram 5]FIG. 1 shows that plasma-derived IgG formulations dose-dependently prevent PA-induced tissue damage. Laser scanning confocal microscopy images of paraffin-fixed MucilAir™ sections were acquired and analyzed for cytokeratin and beta-tubulin expression. Non-infected transwells receiving vehicle alone or IgG formulations served as controls. PA-infected transwells treated with vehicle served as positive controls. Data are representative of three independent experiments. [Figure 6] FIG. 1 shows that plasma-derived immunoglobulin preparations reduce PA-induced IL-8 release by epithelial cells. IL-8 was measured in MucilAir™ basal medium. Non-infected transwells receiving vehicle alone or immunoglobulin preparation served as controls. PA-infected transwells treated with proline served as positive controls. Data are representative of three independent experiments. [Figure 7] FIG. 1 shows that plasma-derived IgG formulations dose-dependently reduce PA-induced IL-8 release by epithelial cells. Relative concentrations of IL-8 secretion were calculated with respect to IL-8 secreted by MucilAir™ when exposed to 10 CFU of PA for 24 hours. Non-infected transwells receiving vehicle alone or immunoglobulin formulation served as controls. PA-infected transwells treated with proline served as positive controls. Data are representative of one experiment using MucilAir™ from three different donors per condition. [Figure 8] FIG. 1 shows that plasma-derived Ab preparations reduce PA-induced IL-6 release by epithelial cells. IL-6 was measured in MucilAir™ basal medium. Non-infected transwells receiving vehicle alone or immunoglobulin preparation served as controls. PA-infected transwells treated with vehicle served as positive controls. Data are representative of three independent experiments. [Figure 9] Figure 1: Plasma-derived Ab preparations interact with human rhinovirus C15. Binding of increasing concentrations of plasma-derived Ab or secretory IgAM to coated HRV C15 as determined by ELISA. [Figure 10] Figure 1 shows that plasma-derived Abs reduce HRV shedding. HRV-C15 genome copy number was measured in apical lavage using q-PCR. Proline-treated HRV-infected transwells served as a positive control for infection. For efficacy measurements, rupintrivir-treated transwells served as a positive control. [Figure 11] FIG. 1 shows that plasma-derived Abs reduce HRV-induced tissue damage. Tissue integrity was assessed by measuring transepithelial electrical resistance. Non-infected transwells treated with proline served as negative controls. HRV-infected transwells treated with proline served as positive controls for infection. For efficacy measurements, rupintrivir-treated transwells served as positive controls. [Figure 12] FIG. 1 shows that plasma-derived Abs prevent HRV-induced reduction in mucociliary clearance. Mucociliary clearance was assessed by measuring the velocity of 30 μm diameter polystyrene microbeads added to the apical surface of the MucilAir™. Non-infected transwells treated with proline served as negative controls. HRV-infected transwells treated with proline served as positive controls for infection. For efficacy measurements, rupintrivir-treated transwells served as positive controls. [Figure 13-1] Figure 2: Plasma-derived immunoglobulin preparations inhibit HRV proliferation in a dose-dependent manner. HRV-C15 genome copy numbers were measured in apical lavage using q-PCR after treatment with different immunoglobulin preparations at 4 μg / well, 20 μg / well, 100 μg / well and 500 μg / well. Proline-treated HRV-infected transwells served as a positive control for infection. For efficacy measurements, rupintrivir-treated transwells served as a positive control. [Figure 13-2] Continued from Figure 13-1. [Figure 14-1]Figure 1 shows that plasma-derived immunoglobulin preparations inhibit influenza virus growth in a dose-dependent manner. Influenza virus genome copy numbers were measured in apical lavage using q-PCR after treatment with different immunoglobulin preparations at 4 μg / well, 20 μg / well, 100 μg / well and 500 μg / well. Influenza virus-infected transwells treated with proline served as a positive control for infection. For efficacy measurements, oseltamivir-treated transwells served as a positive control. [Figure 14-2] Continued from Figure 14-1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0149] The following non-limiting examples serve to illustrate the invention. The studies included in the following examples show that immunoglobulin delivered to airway tissues can combine antibacterial (immune clearance) and anti-inflammatory effects and is therefore an attractive option for the effective treatment or prevention of exacerbations, especially infection-related exacerbations, in subjects suffering from chronic lung diseases such as COPD and NCFB. In particular, preventing chronic infections and acute exacerbations is suitable for maintenance therapy of subjects with these diseases.
[0150] The defense of mucosal surfaces against colonization by microorganisms and against possible invasion and invasion is provided by a combination of constitutive nonspecific substances (mucus, lysozyme and defensins) and also by specific immune mechanisms involving secretory Ig (SIg) at the humoral level [20;21]. In vivo, experimental and clinical resistance to infection can be correlated with specific secretory IgA (SIgA) antibodies (Abs) that function as an immunological barrier at mucosal surfaces [22;23]. The assembly, immobilization and neutralization of pathogens at mucosal surfaces are thought to be facilitated by the multivalency of SIgA [24;25]. SIgM, which functions as a substitute for SIgA in IgA-deficient individuals, appears to act through a similar defense mechanism
[26] .
[0151] For some pathogens, such as poliovirus, Salmonella, or influenza, protection against mucosal infection can be induced by active mucosal immunization with approved vaccines. However, for the vast majority of mucosal pathogens, active mucosal vaccines are not available. Alternatively, protective levels of Abs can be delivered directly to mucosal surfaces by passive immunization. Naturally, this is physiologically achieved in many mammalian species by the transfer of maternal antibodies to the offspring via milk. occurs
[27] . Human and animal studies using passive mucosal immunization have shown that pIgA and SIgA antibody molecules administered orally, intranasally, intrauterinely or by pulmonary instillation can prevent, reduce or cure bacterial and viral infections
[28] . However, the secretory form of IgA naturally found at mucosal surfaces has rarely been used. Large-scale production of SIgA has not been possible to date. Although the construction of SIgA using biotechnological methods is difficult, such molecules could have important clinical applications
[29] . The same is true for secretory component-containing IgM.
[0152] Plasma-derived immunoglobulins have been used for decades to protect immunocompromised patients from potentially fatal infections
[30] . Plasma-derived immunoglobulins are generally highly pure in IgG. However, few IgG products contain concentrated IgM in the formulation (e.g., Pentaglobin™). Delivery of plasma-derived immunoglobulins is intravenous or subcutaneous, ensuring systemic distribution of immunoglobulins throughout the body. Immune replacement therapy has been shown to reduce the incidence of pneumonia in immunocompromised patients, but appears to have limited impact on upper respiratory tract and bronchial infections. Topical application of plasma-derived immunoglobulins may support higher Ig content at mucosal surfaces without increasing systemic Ig delivery.
[0153] HRV and PA were chosen to test the efficacy of plasma-derived immunoglobulins to prevent epithelial tissue infection due to their major role in COPD and NCFB exacerbations. To better mimic the situation in humans, a human primary cell-based airway model, MucilAir™ (Epithelix Sarl, Geneva), was used. MucilAir™ is an in vitro reconstituted cellular model of human airway epithelium. MucilAir™ pools are made from a mixture of nasal or bronchial cells isolated from 14 different donors or just one donor, respectively. Being cultured at the air-liquid interface, the model shows high transepithelial electrical resistance, ciliary beating and mucus production. This proves the full functionality of the epithelial tissue as exists in vivo. Cytokine release (e.g. IL-8 and IL-6) and lactate dehydrogenase (LDH) release are detected during infection, reflecting how infection is associated with inflammation and tissue damage in this model.
[0154] material and method Infection of the airway is initiated by the deposition of pathogenic bacteria and viruses on the apical side of the airway epithelium. To reach tissues, viruses infect epithelial cells, whereas bacteria tend to damage cells through the secretion of exotoxins. To test the efficacy of plasma-derived immunoglobulins in preventing tissue damage, a Pseudomonas aeruginosa infection model was used.
[0155] Bacterial strains Pseudomonas aeruginosa (PA) used in this model was a clinical isolate obtained from the Institute of Infectious Diseases (University of Bern, Switzerland). PA is a pathogenic bacterium that causes disease in humans and is involved in lung infections. PA was cultured on blood agar Petri dishes. Colonies were selected and cultured in Brain Heart Infusion (BHI) medium at 37 °C and 400 revolutions per minute (RPM) for 24 h. The next day, cultures were diluted 1:10 in fresh BHI medium and placed at 37 °C and 400 rpm for an additional hour. OD was then measured and bacterial numbers estimated from OD / bacterial load curves generated with multiple cultures prior to the experiment. An aliquot was withdrawn for further dilution prior to dosing and a second aliquot was withdrawn for further plating on blood agar plates to accurately verify the bacterial load.
[0156] Virus strains Rhinovirus C15 is a clinical isolate obtained from the Geneva Hospital (designation S07-09-08-U). Virus stocks were made in MucilAir™ cultures and diluted in culture medium. They were not purified or concentrated.
[0157] For dose-response studies, rhinovirus C15 (2009) and influenza A / Switzerland / 7717739 / 2013 (H1N1) were isolated with MucilAir™ directly from clinical specimens as described in
[31] . Experimental virus stocks were generated with MucilAir™ and apical washes were collected with culture medium. Productions from several days were pooled, quantified by qPCR, aliquoted and stored at -80°C.
[0158] organization MucilAir™ (Epithelix Sarl, Geneva) was used to mimic human bronchial tissue. For each test group, three MucilAir™ transwells were used, each transwell coming from either one different donor or a mix of the 14 donors used in the dose-response study. MucilAir™ cultures were performed at the air-liquid interface. The medium used on the basal side was MucilAir™ culture medium (Epithelix Sarl, Geneva) containing growth factors and phenol red. The medium does not contain serum.
[0159] Pseudomonas aeruginosa infection model and treatment The infection model using PA is based on the deposition of as few as 10 colony forming units (CFU) of PA onto the apical side of a single MucilAir™ Transwell in a volume of 10 μL. Over a 24 hour period, PA grew to >10 9 CFU / transwell are reached. Infection leads to the release of lactate dehydrogenase (LDH) (associated with tissue damage) as well as proinflammatory molecules such as IL-8 and IL-6. Tissue damage is also evidenced by the appearance of tissue holes and loss of transepithelial electrical resistance.
[0160] In some experiments, immunoglobulins were deposited 10 min before or simultaneously with the bacteria. Immunoglobulins were applied in a final volume of 10 μL. The effect of immunoglobulins was compared to that of a vehicle solution (25 mM proline).
[0161] Human rhinovirus C15 and influenza H1N1 infection models and treatment At time t = 0, the proof-of-concept experiment (Figure 10) had a 3.8 × 10 7 Genome copies / mL HRV C15 (clinical strain: S07-09-08-U) 15 μL stock solution, as well as 1.0 × 10 for both HRV and influenza H1N1 in dose-response studies (Figures 13 and 14). 810 μL of genome copies / mL were applied to the apical side of the MucilAir™ for 3 hours at 34° C. and 5% CO2. Immunoglobulin was applied to the apical surface of the MucilAir™ at the same time as the virus in 5 μL and was refreshed at 3.5 and 24 hours. The effect of immunoglobulin was compared to vehicle solution (25 mM proline). 3 hours after inoculation, the epithelium was washed three times with PBS (Ca2+ / Mg2+) to remove the inoculum.
[0162] Cell-free apical washes (20 min) with 200 μL MucilAir™ culture medium were collected 3.5 h after inoculation, then 24 and 48 h, and stored at -80°C.
[0163] Immunoglobulins A human plasma-derived IgG preparation (IgPro10, Pilivigen) was produced as described
[32] . Preparations containing IgA and IgM were obtained from ion-exchange chromatography subfractions used in the large-scale production of human plasma-derived IgG. The elution fractions containing IgA and IgM were purified by tangential flow filtration (TFF; Pellicon The resulting IgA / M solution, containing IgA and IgM in a 2:1 mass ratio, was further processed to combine recombinant human SC and IgA / M in vitro to obtain SC IgA / M
[33] .
[0164] ELISA Proinflammatory cytokine release by human bronchial tissue upon infection was measured in aliquots of basal medium harvested 24 hours post-infection. In particular, IL-8 (RnD Systems; DY208) and IL-6 (RnD Systems; DY206) were assessed. Measurements were performed according to the user manual.
[0165] For the PA ELISA, PA were cultured overnight at 37°C in BBL Todd Hewitt Broth medium. PA were pelleted by centrifugation (3220 g) for 10 min. The supernatant was removed and the pellet was washed twice with 0.1 M carbonate buffer (pH 9.6). The pellet was resuspended in carbonate buffer and 50 μl / well (4 × 10 6 Bacteria) were added to the polysorbate plates. Coating was performed overnight at 2-8 °C. The next day, the wells were washed for 3 h with PBS / Tween (0.05%) and blocked with PBS / FCS (2.5%) for 1.5 h at room temperature. The wells were then washed for 3 h with PBS / Tween (0.05%). Ig preparations (0.7 μg / ml to 500 μg / ml) were added to the wells at room temperature for 2 h. After two washes with PBS / Tween (0.05%), the secondary antibody, goat anti-human IgG / A / M-HRP (1 mg / ml, 1:2'000 in blocking buffer), was incubated with the samples for 2 h at room temperature. After three final washes with PBS / Tween (0.05%), the TMB substrate for peroxidase was used. The blue precipitate formation is linearly proportional to the amount of enzyme in each well. The enzymatic reaction was stopped with 50 μl / well HCl 1M. Absorbance was read at 450 nm (reference wavelength 620 nm). The average blank absorbance of each triplicate was subtracted from the bacterial coat absorbance.
[0166] For rhinovirus ELISA, Maxisorp plates (Nunc) were pre-filled with purified rhinovirus C stock (3 × 10 6100 µg / ml; clinical name: S07-09-09-U) was coated overnight at 2-4°C. A second Maxisorp plate was coated with 5% BSA in 0.1 M carbonate buffer to serve as the "blank" plate. The next day, the wells were washed 3 times with PBS / Tween (0.05%) and blocked with PBS / FCS (2.5%) for 1.5 h at room temperature. The wells were then washed 3 times with PBS / Tween (0.05%). Ig preparations (0.7 µg / ml to 500 µg / ml) were added to the wells for 2 h at room temperature. After two washes with PBS / Tween (0.05%), the secondary antibody, goat anti-human IgG / A / M-HRP (1 mg / ml, 1:2'000 in blocking buffer), was incubated with the samples for 2 h at room temperature. After three final washes with PBS / Tween (0.05%), the TMB substrate for peroxidase was used. Blue precipitate formation is linearly proportional to the amount of enzyme in each well. The enzyme reaction was stopped with 50 μl / well HCl 1M. Absorbance was read at 450 nm (reference wavelength 620 nm). The average blank absorbance of each triplicate was subtracted from the virus coat absorbance.
[0167] immunohistochemistry Tissue damage was assessed using laser scanning confocal microscopy. Tissues were prepared as follows: MucilAir™ transwells were washed once with PBS and fixed with 4% paraformaldehyde overnight at 4°C. The next day, transwells were washed three times with PBS and tissues were permeabilized with ice-cold methanol at -20°C for 30 min. Tissues were then washed three times with PBS and a blocking step was performed overnight at 4°C using 3% goat serum in PBS. After another washing step with PBS (three times), tissues were stained for 48-72 h at 4°C with anti-cytokeratin antibody (Abcam; ab192643) (1 / 200), anti-beta tubulin antibody (Abcam; ab11309) (1 / 200) and DAPI (Sigma D9542) (1 / 2000), all diluted in PBS. Tissues were then washed three times in PBS and transwells were separated from tissues. The tissues were then mounted on slides, covered with mounting medium and a coverslip. The slides were kept at room temperature for 24 hours to dry and then were then transferred to Zeiss Images were taken with an LSM800 confocal microscope.
[0168] Transepithelial Electrical Resistance (TEER) TEER is a dynamic parameter that reflects the state of the epithelium. However, it is influenced by several factors. For example, if holes are present or if cell tight junctions are lost, the TEER value can drop below 100 Ω.cm. 2 In contrast, when the epithelium is healthy, TEER values typically reach values below 200 Ω.cm 2 Become higher.
[0169] Untreated samples and samples treated with solvent without virus or bacteria served as negative controls, and 10% Triton X-100 was used as a positive control.
[0170] To measure TEER values, 200 μL of MucilAir™ medium was added to the apical compartment of MucilAir™ cultures and resistance was measured for each condition using an EVOMX volt-ohmmeter (World Precision Instruments UK, Stevenage). Resistance values (Ω) were calculated using the following formula: TEER(Ω.cm 2 )=(Resistance value(Ω)-100(Ω))×0.33(cm 2 ) (where 100 Ω is the resistance of the membrane and 0.33 cm 2 is the entire surface of the epithelium) Use TEER(Ω.cm 2 ) was converted to
[0171] Lactate dehydrogenase (LDH) assay Lactate dehydrogenase is a stable cytosolic enzyme that is rapidly released into the culture medium upon rupture of the plasma membrane. 100 μL basal medium was collected at each time point and incubated with the reaction mixture of the Cytotoxicity Detection KitPLUS according to the manufacturer's instructions (Sigma, Roche, 11644793001). The amount of released LDH was then quantified by measuring the absorbance of each sample at 490 nm with a microplate reader. Untreated and solvent (without virus or bacteria) served as negative controls and correspond to physiological release of LDH (≦5%). 10% Triton X-100 was used as a negative control and corresponds to massive LDH release (equal to 100% cytotoxicity). To determine the percentage of cytotoxicity, the following equation was used (A=absorbance value): Cytotoxicity (%) = (A(experimental value) - A(low control) / A(high control) - A(low control)) x 100
[0172] Viral shedding At each time point tested, an apical wash was performed with 200 μL MucilAir™ culture medium. 20 μL was then used for viral RNA extraction (QIAamp® Viral RNA Extraction Kit). The viral RNA was further used in a PCR kit (Qiagen) to obtain an RNA elution volume of 60 μL. 5 μL of viral RNA was used to quantify viral RNA by quantitative RT-PCR (QuantiTect Probe RT-PCR, Qiagen). Two picornavirus family-specific primers, a pan-picornavirus primer and a picornavirus primer, as well as an influenza A-specific primer and a probe with a FAM-TAMRA reporter-quencher dye were also used.
[0173] Four dilutions of known concentrations of HRV-A16 or H3N2 RNA and controls for RT-PCR were included and plates were run on either an Applied Biosystems TaqMan ABI 7000 or Bio-Rad Chromo4 PCR Detection System. Ct data were reported against a standard curve, corrected for dilution factors, and graphed as genome copies per ml.
[0174] Mucociliary clearance Mucociliary clearance was measured using an Olympus BX51 microscope equipped with a 5× objective. Monitored using an attached Sony XCD-U100CR camera. 30 μm diameter polystyrene microbeads (Sigma, 84135) were added to the apical surface of the MucilAir™. Microbead movement was video tracked at room temperature at 2 frames per second for 30 images. Three movies were taken per insert. The average bead movement speed (μm / sec) was calculated with ImageProPlus 6.0 software. Data were expressed as mean + SEM (n=3 inserts). EXAMPLES
[0175] Plasma-derived immunoglobulins interact with Pseudomonas aeruginosa PA is associated with many airway infections, such as in subjects with cystic fibrosis or severe COPD. Many different strains exist. Clinical isolates were used for relevance to the clinical setup. Commercially available plasma-derived immunoglobulins consist primarily of highly purified IgG obtained from plasma pools collected from several thousand healthy adult donors. Due to the multiple donor origin, the isolated immunoglobulins provide higher titers against specific pathogens as well as polyvalency and polyclonality as a result of vaccination. Monomeric IgA, as well as a mixture of pentameric IgM and monomeric / dimeric IgA, can be isolated from the waste fraction. We have previously established that polyreactive serum-derived polymeric IgA, IgM and a mixture of the two isotypes (IgA / M) assemble into secretory Abs when combined with recombinant secretory components (SC)
[34] . In support of their use for local passive immunization, the molecules show high in vitro stability upon exposure to protease-rich intestinal washings
[35] .
[0176] Figure 1 shows the binding of plasma-derived immunoglobulins to PA in an ELISA assay. Importantly, all plasma-derived immunoglobulins were able to bind to PA clinical isolates in this assay (see Materials and Methods section). Binding to PA was dose-dependent, with immunoglobulin amounts ranging from 0.7 μg / mL to 500 μg / mL. Comparison between immunoglobulin preparations showed differences in the binding capacity of PA. For example, a mixture of IgA and IgM, conjugated or not with SC, showed the highest affinity for PA, followed by IgG and IgA. EXAMPLES
[0177] Plasma-derived immunoglobulin IgG forms large aggregates with PA Immunoglobulins may have several roles at mucosal surfaces. They may function as opsonins, leading to enhanced recognition of phagocytes, or promote complement precipitation and subsequent lysis. Immunoglobulins can bind to infected cells, thus tagging them for destruction through a mechanism called antibody-dependent cell-mediated cytotoxicity (ADCC). Immunoglobulins can bind to surface antigens of pathogens, inhibiting their growth and neutralizing the pathogen. Immunoglobulins can also coat pathogens and prevent their adhesion to the mucosal epithelium (a mechanism called immune exclusion). Finally, due to their bivalent or polyvalent binding properties, immunoglobulins may aggregate microorganisms into larger clusters, allowing for more effective recognition by the immune system and mechanical clearance by the host
[36] . Secretory IgA and IgM present at mucosal sites exhibit 4 and 10–12 valencies, respectively. In contrast, IgG exhibits only 2 valencies. IgA and IgM are more prone to result in microbial agglutination than IgG [37;38].
[0178] Figure 2 shows the confocal microscopy analysis of immune complexes formed between IgG and PA. Using CFSE-labeled PA and Cy3-labeled plasma-derived IgG, it was surprising to detect large IgG-PA immune complexes. Antigen binding by immunoglobulins is largely dependent on their antigen-binding (Fab) fragments. Since IgG is only bivalent, it is not expected to observe such aggregates. This result suggests that IgG may possibly be the This may indicate that IgG may further bind to PA outside the Fab region through carbohydrates. IgG may therefore be more potent than expected in signaling the immune system about PA. EXAMPLES
[0179] Plasma-derived immunoglobulin prevents tissue damage induced by PA PA is a pathogen known for its involvement in biofilm formation and its resistance to many antibiotics
[39] . PA presents many virulence factors. Some of them are extracellular enzymes such as elastase A and B, protease IV, exotoxin A, exoenzyme S or hemolysin. The extracellular enzymes function in the defense of PA against components of the immune system as well as in the participation in the virulence of PA and associated tissue damage.
[0180] To assess how well PA induces tissue damage in our infection model, we measured the release of lactate dehydrogenase (LDH), which is associated with the rupture of the plasma membrane. Experiments were performed in our primary 3D cell culture system, and LDH was measured in samples harvested 24 hours after infection. All immunoglobulin preparations (e.g., IgG, IgA, IgAM, and sIgAM) proline (vehicle) were tested. Figure 3 shows that PA infection induces the release of LDH at levels above the normal LDH levels found in the steady-state medium. Importantly, when immunoglobulins were given together with PA, all immunoglobulin preparations were shown to prevent the release of LDH and therefore tissue damage.
[0181] Another way to evaluate tissue damage is to measure the transepithelial electrical resistance (TEER) of tissues in vitro. Indeed, this parameter reflects the integrity of tight junction dynamics in cell culture models of epithelial monolayers or multilayers
[40] . As a result, TEER decreases when tissue integrity is affected. To understand how PA infection affects the barrier equivalent to primary epithelial tissue, TEER was measured before and 24 h after infection. Figure 4 shows how tissue integrity is affected by infection and what role IgG plays in its prevention. Maximal doses of IgG and proline did not affect TEER when bacteria are not present on the apical side of the transwell. PA infection not only releases LDH as can be seen in Figure 3, but also reduces TEER (proline sample). This result points out the loss of tissue integrity of MucilAir™ when PA is added. To evaluate the activity of IgG in this context, increasing doses of IgG (doses ranging from 5 to 500 μg) in combination with PA were used. The lowest IgG dose did not provide good protection against tissue damage, whereas increasing doses (50-500 μg) provided good tissue protection, with the two highest doses being the most effective.
[0182] In addition to LDH release and TEER measurements, MucilAir™ tissues were examined using a microscope to evaluate the damage caused during PA infection. Confocal microscopy was used since MucilAir™ is a multilayered epithelial tissue. The same setup described for Figure 4 was used. 24 hours after infection, tissues were fixed and cut on slides for staining and analysis. Figure 5 shows the efficacy of IgG in preventing PA-induced tissue damage. Healthy tissue (control) is represented by the section appearing in the bottom row, far right. Upon PA infection, large holes appear in the tissue (transwells treated with proline; top row, left). Increasing doses of IgG were applied together with PA (doses ranging from 5 to 500 μg). A dose-dependent effect of IgG in preventing tissue damage was observed. The lowest IgG dose did not prevent tissue damage, but seemed to have some effect, as the holes presented a smaller surface area. Increasing IgG doses were associated with an absence of holes. However, for doses of 50 to 250 μg, tissue damage was still observable. 500 μg IgG gave the best results, with tissues looking as good as in the control wells.
[0183] In summary, all plasma-derived immunoglobulin preparations were able to prevent LDH release. Using IgG, we detailed the mechanism of action behind this result, demonstrating that immunoglobulins can prevent loss of tissue integrity and tissue damage. EXAMPLES
[0184] Plasma-derived immunoglobulin prevents Pseudomonas aeruginosa-induced tissue release of proinflammatory cytokines Epithelial tissues in the mucosal environment function as a barrier to the outside world, physically preventing microorganisms from invading the tissue. However, once damaged, microorganisms can freely enter. Therefore, to signal potential infection and damage of these barriers, epithelial tissues interact with the immune system through the secretion of "danger" signals or cytokines, alerting cellular components of the immune system to migrate to the tissue and provide a second layer of defense.
[0185] IL-6 and IL-8 are proinflammatory cytokines secreted by epithelial tissues when these tissues are invaded. In the next set of experiments, plasma-derived immunoglobulins were evaluated in preventing proinflammatory cytokine release upon PA infection. Figure 6 shows IL-8 release by MucilAir™ 24 hours after PA infection. All immunoglobulin preparations (e.g., IgG, IgA, IgAM and sIgAM) were tested along with proline (solvent). Figure 6 shows that IL-8 secretion was highly increased during PA infection, reaching a nearly three-fold increase. None of the immunoglobulin preparations significantly affected IL-8 release by tissues at steady state. However, when applied together with PA, all immunoglobulin preparations were able to prevent PA-induced secretion of IL-8.
[0186] To see the effect of IgG in preventing PA-induced IL-8 release, increasing doses of IgG (doses ranging from 5 to 500 μg) were tested in combination with PA. Figure 7 details the dose response of IL-8 secretion to IgG. The experiment was performed with MucilAir™ generated from three different donors. To account for donor-to-donor variability, post-infection IL-8 secretion was set in combination with proline as the 100% release condition. Additional conditions were calculated in relation to 100% release. As shown in Figure 7, the maximum doses of IgG and proline did not affect IL-8 release. Interestingly, IgG substantially reduced PA-induced IL-8 secretion in a dose-dependent manner, with the best effect being obtained at the maximum dose (500 μg).
[0187] Similarly, IL-6 secretion after PA infection was examined. Figure 8 shows IL-6 release by MucilAir™ 24 hours after PA infection. All immunoglobulin preparations (e.g., IgG, IgA, IgAM and sIgAM) were tested together with proline (vehicle). Figure 8 shows that IL-6 secretion was highly increased by PA, reaching a nearly 6-fold increase. None of the immunoglobulin preparations significantly affected IL-6 release by tissues at steady state. However, when applied together with PA, all immunoglobulin preparations were able to prevent PA-induced secretion of IL-6.
[0188] Taken together, this data set indicates that all immunoglobulin preparations may prevent the release of proinflammatory cytokines such as IL-6 and IL-8 and reduce local inflammation in PA-infected subjects who received topically applied immunoglobulin as prophylaxis. Prevention of IL-8 and IL-6 secretion during PA infection may indeed translate to prevention of tissue damage by topically applied immunoglobulin against PA. Plasma-derived immunoglobulin may act via immune clearance against PA and by inhibition of extracellular enzyme activity. EXAMPLES
[0189] Plasma-derived immunoglobulins interact with human rhinoviruses HRV is primarily known to be involved in over half of cold-like illnesses,
[41] but has also been implicated in chronic obstructive pulmonary disease (COPD) and asthma exacerbations. There are more than 100 serotypes. To evaluate whether nebulized plasma-derived immunoglobulins can protect humans from HRV infection, we tested the binding of clinical isolates of HRV by various plasma-derived immunoglobulins. Figure 9 shows that all immunoglobulin preparations were able to bind HRV in a dose-dependent manner at doses ranging from 0.7 μg / mL to 500 μg / mL in an ELISA assay (see Materials and Methods section). However, binding differed between each immunoglobulin preparation. IgG was a less potent binder, while IgAM and IgA showed good binding. Adding SC to IgAM seems to reduce the potency of IgAM binding to HRV. It can be noted that some of the binding is not Fab-dependent. EXAMPLES
[0190] Plasma-derived immunoglobulin prevents shedding and tissue damage induced by human rhinovirus Like other viruses, HRV infects cells so that it can replicate. In the next step, virions are then assembled and packaged prior to cellular transport / excretion by cell lysis. Figure 10 shows the effect of plasma-derived immunoglobulins to prevent HRV excretion after MucilAir™ infection. When a solvent control (proline) was used, high excretion of PA (approximately 10 9 HRV C15 genome copies / mL) was detected at the apical side of MucilAir™. As a positive control, rupintrivir, a rhinovirus 3C protease inhibitor against human rhinovirus, was used. As observed, application of rupintrivir effectively reduced HRV shedding by 3 logs. Surprisingly, application of plasma-derived immunoglobulin at the time of infection completely reduced HRV shedding to levels undetectable by our assay. All immunoglobulin preparations except IgAM were able to show such reduction. However, and importantly, IgAM was still able to reduce HRV shedding by at least 4 logs.
[0191] Plasma-derived immunoglobulins could therefore prevent HRV entry into the epithelium and hence subsequent HRV replication and spread.
[0192] During replication, HRV can result in cell lysis. In the context of epithelium, we evaluated whether plasma-derived immunoglobulins can protect epithelial cells against HRV-induced tissue damage. To assess this, we used the TEER parameter as a means of assessing tissue integrity after HRV infection (Figure 11). At steady state (no infection), TEER measurements after treatment with solvent (negative control) were approximately 260 Ohm.cm 2When the solvent was applied to the tissue (positive control) after HRV infection, the TEER decreased almost 5-fold, pointing to the loss of tissue integrity after infection. As shown in Figure 11, rupintrivir had a positive effect in preventing HRV-induced tissue damage. All plasma-derived formulations were able to prevent the loss of tissue integrity when HRV was given. Immuno-elimination of HRV by plasma-derived immunoglobulins proved to be sufficient to protect lung tissue against PA infiltration and PA-induced cell damage. EXAMPLES
[0193] Plasma-derived immunoglobulin reduces the impairment of human rhinovirus-induced mucociliary clearance Mucociliary clearance is an important function of bronchial tissue. Pathogens trapped in mucus are expelled to the lungs and expectorated to prevent pathogens from lodgement and replicating in lung tissue. Mucociliary clearance can be influenced by different mechanisms, one of which is tissue damage.
[0194] Since HRV infection is associated with tissue damage, we assessed the effect of plasma-derived immunoglobulins on mucociliary clearance 48 hours after HRV infection (Figure 12). At steady state (no infection), mucociliary clearance was approximately 40 mm / s after treatment with vehicle (negative control). Application of vehicle to tissues (positive control) after HRV infection reduced mucociliary clearance by 2-fold. As shown in Figure 12, rupintrivir had a positive effect in preventing the HRV-induced decrease in mucociliary clearance. All plasma-derived preparations were able to prevent the decrease in mucociliary clearance. The best effect was obtained for IgA and IgM, for which no loss of mucociliary clearance was observed. EXAMPLES
[0195] Dose-dependent efficacy of human plasma-derived immunoglobulin preparations against human rhinovirus infection We next investigated whether the observed effects were dose-dependent. The immunoglobulin preparations were added at 4, 20, 100 and 500 μg / well, and their effects on HRV expansion were assessed by measuring HRV genome copy number. Figure 13 shows that the plasma-derived human immunoglobulin preparation was able to inhibit HRV expansion in a dose-dependent manner.
[0196] The effect on TEER was also investigated as described above. Immunoglobulin preparations delayed the HRV-induced TEER decrease at 4 μg / well, 20 μg / well, and 100 μg / well. At 500 μg / well, the decrease was completely prevented.
[0197] Furthermore, the effect of different doses of immune globulin preparations on cilia beating frequency and mucociliary clearance was evaluated using the same doses as above. Again, a dose-dependent effect on cilia beating frequency and mucociliary clearance was observed with all immune globulin preparations tested.
[0198] HRV-induced IL-8 secretion on day 2 postinfection was also inhibited by plasma-derived immunoglobulin preparations; even 4 μg / well IgAM and SIgAM achieved complete inhibition; IgG and IgA achieved highly significant reductions at 4 μg / well, with all immunoglobulin preparations achieving complete inhibition at higher doses. HRV-induced production of RANTES was also significantly inhibited by the lowest dose of immunoglobulin used (4 μg / ml) and was completely inhibited by the higher doses of all immunoglobulin preparations at the 2-day time point.
[0199] In summary, plasma-derived immunoglobulins were able to protect lung tissue in vitro against HRV infection and its associated tissue damage. Local prophylactic application of plasma-derived immunoglobulins to the lungs of subjects at risk for pulmonary infections would provide protection against microorganisms of viral or bacterial origin. EXAMPLES
[0200] Efficacy of human plasma-derived immunoglobulin preparations against influenza virus infection Using influenza strain H1N1, the experiment was set up using the same protocol for rhinovirus infection of MucilAir™ cultures. Oseltamivir was used as a positive control at 10 μg / well. As shown in Figure 14, all immunoglobulin preparations were shown to reduce influenza spread in a dose-dependent manner.
[0201] The perturbation of TEER caused by influenza virus was also reduced by 4 μg / well and 20 μg / well of each immunoglobulin preparation, and was completely prevented by 100 μg / ml and 500 μg / well.
[0202] An influenza virus-induced decrease in cilia beating frequency was observed on day 4 post-infection. IgG showed the best rescue effect on cilia beating frequency, with a complete recovery already at 4 μg / well. IgA, IgAM and sIgAM preparations were also able to rescue cilia beating frequency, but only at 20 μg / well and higher concentrations. The Ig preparations also restored mucociliary clearance and reduced influenza-induced IL-8 secretion and influenza It also reduced the α-induced RANTES secretion. EXAMPLES
[0203] Nebulized plasma-derived immunoglobulin prevents airway infection-induced exacerbations in subjects with chronic obstructive pulmonary disease (COPD) and / or non-cystic fibrosis bronchiectasis (NCFB) Subjects with COPD and / or NCFB are susceptible to chronic airway infections that may contribute to the exacerbation of their disease. The chronicity of these infections drives tissue remodeling in the subject, increasing the severity of the disease.
[0204] As shown in the examples above, topically applied plasma-derived immunoglobulins prevented bacterial and viral adhesion and invasion in primary human airway tissue in vitro. Immunoexclusion of these microorganisms prevented tissue damage and, indirectly, the release of proinflammatory cytokines and loss of mucociliary clearance.
[0205] To break the chronicity of these infections, subjects with NCFB or mild to severe COPD potentially associated with NCFB are treated with nebulized plasma-derived immunoglobulin once or twice daily. Plasma-derived immunoglobulin formulated in a 50 mg / mL to 150 mg / mL solution is nebulized using an active vibrating mesh nebulizer. 2-10 mL of the plasma-derived immunoglobulin preparation is applied daily in the morning and / or evening.
[0206] Reducing infection-induced exacerbations would reduce local inflammation in COPD and NCFB subjects and slow disease progression.
[0207] It will be understood that the invention has been described by way of example only and modifications may be made within the scope and spirit of the invention.
[0208] References [1] Vestbo et al. (2013) Am J Respir Crit Care Med 187(4):347-65. [2] Flume et al. (2018) Lancet 392(10150):880-90. [3] Chalmers et al. (2018) Am J Respir Crit Care Med 197(11):1410-20. [4] Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 report; Global initiative for chronic obstructive lung disease (GOLD). [5] Mohan A et al. (2010) Respirology 15(3):536-42. [6] Molyneaux et al. (2013) Am J Respir Crit Care Med 188(10):1224-31. [7] Hassett et al. (2014) J Microbiol 52(3):211-26. [8] Miravitlles et al. (2017) Respiratory Research 18:198. [9] Singanayagam et al. (2018) Nature Communications 9(1):2229.
[10] British Thoracic Society: Guideline for non-CF Bronchiectasis (2010) Thorax vol. 65, Supp. 1.
[11] Spirometry for health care providers (June 2010). Published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
[12] Published by the Association for Respiratory Technology and Physiology (www.artp.org.uk).
[13] Agarwal and Cunningham-Rundles (2007) Ann Allergy Asthma Immunol. 99(3):281-3.
[14] Normansell (1982) CRC critical reviews in clinical laboratory sciences 17(2):103-66.
[15] Hill et al. (1998) Thorax 53:463-8.
[16] Stucki et al. (2008) Biologicals 36(4):239-47.
[17] WO / 2012 / 030664.
[18] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.
[19] Donaldson and Wedzicha (2014) Int J of COPD 9:1101-10.
[20] Chairatana and Nolan (2016) Crit. Rev. Biochem. Mol. Biol. 113:1-12.
[21] Mantis et al. (2011) Mucosal Immunol. 4:603-11.
[22] Corthesy (2013) Autoimmun. Rev. 12:661-5.
[23] Strugnell and Wijburg (2011) Nat. Rev. Microbiol. 8:656-67.
[24] Mathias et al. (2013) Infect. Immun. 81:3027-34.
[25] Levinson et al. (2015) Infect. Immun. 83:1674-83.
[26] Brandtzaeg (2009) Scand. J. Immunol. 70:505-15.
[27] Brandtzaeg (2003) Vaccine 21:3382-88.
[28] Corthesy (2003) Curr. Pharm. Biotechnol. 4:51-67.
[29] Corthesy (2002) Trends Biotechnol. 20:65-71.
[30] Lucas et al. (2010) J Allergy Clin Immunol. 125(6):1354-60.
[31] Essaidi-Laziosi et al. (2018) J. Allergy Clin Immunol. 141(6):2074-2084
[32] Cramer et al. (2009) Vox Sang. 96:219-25.
[33] Phalipon et al. (2002) Immunity 17:107-15.
[34] Longet et al. (2013) J. Biol. Chem. 288:4085-94.
[35] Crottet and Corthesy (1998) J. Immunol. 161:5445-53.
[36] Roche et al. (2015) mucosal immunology 8(1):176-85.
[37] Bioley et al. (2017) Front Immunol. 8:1043.
[38] Longet et al. (2014) JBC 289(31):21617-26.
[39] Azham et al. (2018) Drug Discov Today S1359-6446(18):30235-6.
[40] Srinivasan et al. (2015) J Lab Autom 20(2):107-26.
[41] Jacobs et al. (2013) Clinical Microbiology Reviews 26(1):135-62.
Claims
1. 1. A composition comprising a polyclonal immunoglobulin for use in preventing or treating an acute exacerbation in a human subject with chronic lung disease, the composition comprising at least 95% human plasma-derived IgG, the composition being administered to the respiratory tract of the subject, the subject having a respiratory tract infection caused by a virus.
2. 2. The composition for use according to claim 1, wherein the chronic lung disease is chronic obstructive pulmonary disease (COPD).
3. 3. The composition for use according to claim 2, wherein the COPD is moderate to severe COPD.
4. The composition for use according to any one of claims 1 to 3, wherein the chronic lung disease is non-cystic fibrosis bronchiectasis (NCFB).
5. A composition for use according to any one of claims 1 to 4 for use in the prevention of acute exacerbations of COPD and / or NCFB.
6. The composition for use according to any one of claims 1 to 5, wherein the subject has low IgG levels, for example plasma levels below 700 mg / dL.
7. The composition for use according to any one of claims 1 to 6, wherein the subject has low IgG levels in sputum.
8. The composition for use according to any one of claims 1 to 7, wherein the subject has experienced one or more acute exacerbations in the 12 months prior to initiating prophylaxis or treatment.
9. The composition for use according to any one of claims 1 to 8, wherein the subject has one or more detectable pro-inflammatory cytokines, such as IL-1b and / or IL-6 and / or IL-8, in his or her sputum.
10. The composition for use according to any one of claims 1 to 9, wherein the subject is suffering from pneumonia.
11. The composition for use according to any one of claims 1 to 10, wherein the subject has a rhinovirus infection.
12. The composition for use according to any one of claims 1 to 11, wherein the polyclonal immunoglobulin reduces inflammation in the airways of a subject.
13. The composition for use according to any one of claims 1 to 12, wherein the polyclonal immunoglobulin reduces the levels of one or more pro-inflammatory cytokines, such as IL-1b and / or IL6 and / or IL8, in the airways of a subject.
14. The composition for use according to claim 10 or 11, wherein the polyclonal immunoglobulin reduces direct damage to the epithelial tissue of the subject caused by at least one pathogen, for example the polyclonal immunoglobulin reduces the activity of extracellular enzymes, reduces loss of epithelial barrier integrity, and / or reduces viral shedding.
15. A composition for use according to any one of claims 1 to 14, comprising human plasma-derived IgG having at least 98% IgG.
16. 16. The composition for use according to claim 15, comprising proline, for example about 210 to about 290 mmol / L L-proline, preferably about 250 mmol / L L-proline.
17. A composition for use according to any one of claims 1 to 16, which is administered as an aerosol.
18. The composition for use according to any one of claims 1 to 17, which is an aqueous solution having a polyclonal immunoglobulin concentration of 50 mg / mL to 150 mg / mL, for example about 100 mg / mL.
19. The composition for use according to any one of claims 1 to 18, administered in a volume of 2 to 10 mL.
20. The composition for use according to any one of claims 1 to 19, which is administered once every 48 hours or once every 24 hours or once every 12 hours during treatment.
21. The composition for use according to any one of claims 1 to 20, which is administered in autumn and winter.
22. 22. The composition for use according to any one of claims 1 to 21, administered in combination therapy with one or more of an antibiotic, a corticosteroid, a beta2 agonist and an anticholinergic bronchodilator.
23. 20. The composition of claim 17, which is a dry powder.
